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ABSTRACT
The Effects of Cannabinoids on Stress-Coping Behaviors and Neuroendocrinological
Measures in Chronic Unpredictable Stress: A Preclinical Systematic
Review and Meta-Analysis
by

Noa Reuveni, Master of Science
Utah State University, 2021
Major Professors: Dr. Sara Freeman and Dr. Scott Bates
Department: Psychology
Preclinical neuroscience research presents contradictory evidence in support of
both protective and destructive effects of cannabinoids in the context of chronic
unpredictable stress. Cannabis, one of the most commonly abused drugs, affects the
hypothalamic pituitary adrenal axis stress response, similarly to other drugs of abuse.
Compared to other drugs of abuse, cannabis primarily interacts with the endogenous
cannabinoid system. The endogenous cannabinoid system has been recently identified to
facilitate both activation and termination of the hypothalamic pituitary adrenal axis stress
response. This systematic review and meta-analysis summarizes the existing preclinical
literature on the effects of cannabinoid administration in the chronic unpredictable stress
model of depression. Scopus, Embase, Psychology & Behavioral Sciences Collection,
APA PsychINFO, PubMed, CINAHL Complete, and ProQuest Dissertations & Theses
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Global were systematically searched for articles that met inclusion criteria and the
standardized mean differences were calculated for each continuous behavioral measure
between vehicle chronic unpredictable stress groups and cannabinoid-treated chronic
unpredictable stress groups. The overall effect of cannabinoids on depressive-like
behavior was evaluated using a multi-level mixed effects model with effect size weights
nested within control groups to address dependency between measurements compared to
same control group. A total of 26 preclinical articles were included. Overall, cannabinoid
administration rescued the negative effects of chronic unpredictable stress on anhedonia,
learned helplessness, novelty suppressed feeding, and exploration anxiety with a pooled
standardized mean difference of 0.4456 (95% CI 0.0498 – 0.8415, p = 0.0274).
Moderator analyses revealed that this effect significantly increased with an increasing
number of cannabinoid administrations and doses. Furthermore, this effect was
significantly greater in mice, with cannabinoids that enhances the endogenous
cannabinoid system, with cannabinoid treatments that are not co-treatments, and when
the cannabinoid is administered during chronic unpredictable stress. These findings
suggest that cannabinoids may be a viable treatment for stress-related psychopathologies
but further investigation is needed into the sample characteristics where cannabinoids are
more efficacious in order to properly assess the benefits of cannabinoid-based
pharmacotherapies.
(96 Pages)
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PUBLIC ABSTRACT

The Effects of Cannabinoids on Stress-Coping Behaviors and Neuroendocrinological
Measures in Chronic Unpredictable Stress: A Preclinical Systematic
Review and Meta-Analysis
Noa Reuveni

It is unclear if cannabis helps individuals cope with life’s stressors or increases
the likelihood of developing stress-related disorders such as depression. Chronic
unpredictable stress is a validated model of depression that exposes rodents to a series of
frequently-occurring, intermittent stressors over the course of a few weeks. This
systematic review and meta-analysis summarizes existing research using rodents on the
effects of cannabinoids on stress-coping behaviors and neuroendocrinological
measurements in chronic unpredictable stress. Databases were systematically searched
for articles that met inclusion criteria, and effect sizes between control chronic
unpredictable stress groups and cannabinoid-treated chronic unpredictable stress groups
were calculated. A meta-analysis of the 26 included articles indicated that cannabinoids
prevent the negative effects of chronic unpredictable stress, suggesting that the
development of cannabinoid-based drugs has the potential to treat stress-related disorders
such as depression.
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CHAPTER I
INTRODUCTION
Importance
According to the World Health Organization, “depression is a leading cause of
disability worldwide” ("Depression," 2020). Depression can lead to suicide, which is the
“second leading cause of death in 15-29-years-olds” ("Depression," 2020). Furthermore,
the global impact of depression and related disorders continue to increase ("Depression,"
2020). Current antidepressants have therapeutic delays, low efficacy, and increased risk
of suicide indicating a need for alternative pharmacotherapies for depression (Fang &
Wang, 2018; Xu et al., 2019).
Mounting preclinical evidence suggests that pharmacological enhancement of the
endogenous cannabinoid system (ECS) promotes antidepressant and anxiolytic effects
(Bortolato et al., 2007; Campos et al., 2013; Fogaça, Campos, Coelho, Duman, &
Guimarães, 2018; Gáll et al., 2020; García-Gutiérrez, Pérez-Ortiz, Gutiérrez-Adán, &
Manzanares, 2010; Hwang et al., 2020; Jankovic, Spasojevic, Ferizovic, Stefanovic, &
Dronjak, 2020; Jin, Yu, Tian, Zhang, & Quan, 2015; Segev, Rubin, Abush, RichterLevin, & Akirav, 2014; H.-n. Wang et al., 2014; Xu et al., 2019; Zhang et al., 2015;
Zhong et al., 2014). Clinically, cannabis is the most commonly abused illicit drug
worldwide, due to reported effects on relaxation and well-being (Volkow, Hampson, &
Baler, 2017). However, chronic cannabis use appears to dysregulate the hypothalamicpituitary-adrenal (HPA) axis, thereby increasing the likelihood of developing stressrelated psychopathologies such as depression (Hillard, Beatka, & Sarvaideo, 2018;
McEwen, 2003).
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Aims
This research aims to identify the conditions in which exogenous administration
of cannabinoids (CBs) promotes stress vulnerability (thereby increasing the likelihood of
developing stress-related psychopathologies such as depression) and the conditions in
which exogenous administration of CBs promote stress resilience (to advance the
development of pharmacotherapies for stress-related psychopathologies). A preclinical
meta-analysis poses a unique benefit in comprehensively organizing existing evidence.
Moderator analyses can identify characteristics which influence the overall effect of CBs
in chronic unpredictable stress (CUS) and sources of between study heterogeneity in
effect sizes. Identification of significant moderators can provide guidance for the
experimental design of future preclinical studies (Vesterinen et al., 2014). The purpose of
this guidance is to facilitate the development of CB-based pharmacotherapies by
identifying gaps in the literature, encouraging preclinical research designs with greater
external validity, and discouraging unnecessary preclinical research designs (Leenaars et
al., 2012; Vesterinen et al., 2014).
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CHAPTER II
LITERATURE REVIEW
Stress and The Hypothalamic Pituitary Adrenal Axis
Life is full of stressors or stimuli which are perceived as threats (Franklin, Saab,
& Mansuy, 2012). These stressors, whether they are physical or psychological, provoke
evolutionarily conserved physiological responses such as the sympatho-adrenomedullary
and HPA axes (Ulrich-Lai & Herman, 2009). This thesis focuses on unpredictable
psychological stressors and the HPA axis: the neuroendocrinological response involved
in chronic stress (Ulrich-Lai & Herman, 2009).
Stress reactivity varies between individuals (Franklin et al., 2012). Stress resilient
individuals demonstrate adaptive responses to stress referred to as allostasis (Franklin et
al., 2012; McEwen, 2003; Ulrich-Lai & Herman, 2009). In contrast to stress resilient
individuals, stress vulnerable individuals are susceptible to allostatic overload or a “wear
and tear” of their stress response, thereby increasing the likelihood of developing a wide
variety of stress-related psychopathologies such as anxiety, post-traumatic stress disorder,
and substance use disorder (Franklin et al., 2012; McEwen, 2003; Ulrich-Lai & Herman,
2009). This thesis will exclusively focus on major depressive disorder (MDD) because it
is modeled in laboratory rodents by the CUS paradigm (Franklin et al., 2012; Katz, 1982;
P. Willner, Towell, Sampson, & Sophokleous, 1987).
In order to effectively treat stress-related psychopathologies such as MDD, it is
imperative to elucidate the etiology of stress resilience and stress vulnerability (Franklin
et al., 2012). According to the stress inoculation model, acute early-life stress can
promote stress resilience (Franklin et al., 2012). This acute stress is beneficial because it
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teaches the individual to actively cope with the stress by problem solving or by seeking
social support (Franklin et al., 2012). In contrast, there is a correlation between childhood
maltreatment and the likelihood of developing stress-related psychopathologies later in
life (Franklin et al., 2012). Severe early-life stress teaches individuals to passively cope
with stressors by avoiding conflict and disengaging behaviorally, characteristics which
are observed in MDD (Franklin et al., 2012). The severity of a stressor depends upon its
predictability, since unpredictable stressors are harder to control and circumvent
(Franklin et al., 2012). In addition to predictability, the frequency and duration of stress
contributes to a shift from allostasis to allosteric overload (Franklin et al., 2012;
McEwen, 2003).
To effectively model chronic and unpredictable stress, the CUS paradigm exposes
rodents to a variety of frequently-occurring, intermittent stressors, for several weeks
(Franklin et al., 2012). CUS induces passive-coping behaviors such as learned
helplessness (e.g. increased immobility in the Porsolt forced swim test) and anhedonia
(i.e. reduced interest in sweetened water) that reflects the diagnostic criteria of MDD
(Franklin et al., 2012; Porsolt, Le Pichon, & Jalfre, 1977). The CUS paradigm was
originally proposed by Richard Katz (Katz, 1982). Then the CUS model was validated by
Willner and colleagues, who showed that CUS-induced anhedonia could be reversed with
chronic (but not acute) antidepressant treatment (Bortolato et al., 2007; Paul Willner,
1984; P. Willner et al., 1987). This result demonstrated the paradigm’s high predictive
validity (Bortolato et al., 2007; Paul Willner, 1984; P. Willner et al., 1987).
In support of the predictive validity of this model, stimulants, which can result in
false positives for acute stress models of depression, do not reverse depressive symptoms
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in CUS (Bortolato et al., 2007). This paradigm also has high construct validity because
rodents can either demonstrate active-coping behaviors such as exploratory activity or
passive-coping behaviors such as learned helplessness (Franklin et al., 2012; Paul
Willner, 1984). Additionally, this paradigm has high face validity demonstrated in
chronic elevations of the stress hormone corticosterone (CORT) or cortisol observed in
both rodents and MDD patients, respectively (Franklin et al., 2012; McEwen, 2003; Paul
Willner, 1984).
Contributing to the face validity of the paradigm, CUS also results in variability in
responses, which is comparable to how humans differently respond to stressors (Franklin
et al., 2012). Furthermore, there are strain differences in stress reactivity with BALB/c
mice being considered stress vulnerable, C57BL/6J mice being considered stress resilient,
and CD1 mice demonstrating more variability in stress reactivity (Franklin et al., 2012).
Most importantly, rodents exposed to CUS demonstrate sexual dimorphisms in HPA axis
activity, which accurately reflect the increased prevalence of stress-related
psychopathologies in females compared to males when investigating the
neuroendocrinology of stress (Franklin et al., 2012).
The neuroendocrinology of stress encompasses a wide variety of
neurotransmitters, neuromodulators, neurotrophic factors, neuropeptides, and hormones
that are beyond the scope of this thesis, which aims to provide a generalized introduction
to the HPA axis (Franklin et al., 2012; Ulrich-Lai & Herman, 2009). Prior to HPA axis
activation, limbic stress circuits consisting of the prefrontal cortex (PFC), hippocampus,
and amygdala are involved in the regulation of stress (Ulrich-Lai & Herman, 2009).
These stress excitatory circuits and stress inhibitory circuits overlap with regions such as
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the bed of the nucleus stria terminalis (BNST) to integrate information regarding the
stressor (Ulrich-Lai & Herman, 2009). The PFC is likely the principle coordinator of
psychological reactivity to stress (Ulrich-Lai & Herman, 2009). In the rodent brain, the
PFC is composed of the prelimbic cortex (PrL) and infralimbic cortex (IL) which both
relay to regions such as the basolateral amygdala (BLA), resulting in overall inhibitory
and excitatory effects of the HPA axis, respectively (Ulrich-Lai & Herman, 2009). The
BLA relays through the BNST to provoke activation of the HPA axis (Ulrich-Lai &
Herman, 2009). In contrast, the ventral subiculum of the hippocampus is the main region
inhibiting the activation of the HPA axis (Ulrich-Lai & Herman, 2009).
Ultimately, HPA axis activation begins with the paraventricular nucleus of the
hypothalamus (PVN) secreting corticotropin-releasing hormone (CRH) into the portal
vein (Franklin et al., 2012; Ulrich-Lai & Herman, 2009). CRH binds to CRH receptor 1
(CRHR1) in the anterior pituitary to secrete adrenocorticotropic hormone (ACTH) into
the bloodstream (Ulrich-Lai & Herman, 2009). ACTH binds to receptors on the zona
fasciculate of the adrenal cortex, causing the secretion of glucocorticoids (GC) (i.e.
CORT) (Ulrich-Lai & Herman, 2009). These GC initiate negative feedback of the HPA
axis, thereby terminating HPA axis activity by binding to GC receptors (GRs) in regions
such as the hypothalamus, hippocampus, amygdala, and PFC (Franklin et al., 2012;
Hillard et al., 2018; Ulrich-Lai & Herman, 2009). Regions such as the hippocampus are
in turn affected by GCs (Franklin et al., 2012). High circulating levels of GCs in
instances of chronic stress can decrease GR expression and increase dendritic atrophy,
thereby contributing to the reduction of hippocampal volume observed in MDD (Franklin
et al., 2012; Ulrich-Lai & Herman, 2009).
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The Endogenous Cannabinoid System and Cannabinoids
The fundamental elements of the ECS consists of the cannabinoid one receptor
(CB1R), the cannabinoid two receptor (CB2R), the endogenous cannabinoid (eCB)
arachidonoyl-ethanolamide (i.e. anandamide) (AEA), the eCB 2-arachidonoyl glycerol
(2-AG), and the enzymes involved in eCB synthesis and catabolism (Lu & Mackie,
2016). eCBs are called retrograde messengers because their synthesis and immediate
diffusion from the postsynaptic membrane via enzymatic reactions contrasts classical
exocytosis of synaptic vesicles (containing pre-synthesized neurotransmitters) from the
presynaptic membrane (Lu & Mackie, 2016).
CB1R and CB2R are !!/# type G-protein coupled receptors (GPCRs) which
inhibit adenylyl cyclase (AC), inhibit calcium channels, activate mitogen-activated
protein kinase (MAPK), and activate potassium channels, thereby preventing
depolarization and neurotransmitter release (Lu & Mackie, 2016). CB1R is the most
abundant GPCR in the central nervous system, especially in the hippocampus, cortex,
basal ganglia, and cerebellum (Lu & Mackie, 2016; Volkow et al., 2017). CB1Rs are
typically located on presynaptic membranes on inhibitory GABAergic neurons (such as
medium spiny neurons) but are also present on excitatory glutamatergic neurons (Lu &
Mackie, 2016). In comparison, CB2Rs are typically located on immune cells such as
microglia and endothelial cells, with increasing expression in response to inflammation
(Hillard et al., 2018; Lu & Mackie, 2016). Beyond the fundamental cannabinoid (CB)
receptors, several subtypes of transient receptor potential (TRP) channels, nuclear
receptors such as peroxisome proliferator activated receptors (PPARs), orphan GPCRs,
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and more are activated by eCBs (Lu & Mackie, 2016; Morales & Reggio, 2019). The role
of these receptors in the extended ECS remains as a topic of on ongoing investigation.
The ECS modulates synaptic transmission throughout the brain. In synapses, eCB
phospholipid precursors are present on the lipid membrane of the postsynaptic neuron in
order to be released on demand in response to !$ GPC activation and/or depolarization
(Hillard et al., 2018; Lu & Mackie, 2016). The synthesis and release of eCBs mediates
short-term plasticity regarded as metabotropic-induced suppression and depolarizationinduced suppression of inhibition or excitation, respectively (depending on the location of
the CB1R on the presynaptic neuron) (Lu & Mackie, 2016). Phospholipase C (PLC),
which can be activated by !$ GPCs, is also sensitive to intracellular calcium, acting as a
coincidence detector to synthesize eCBs (Hillard et al., 2018; Lu & Mackie, 2016). While
PLC is involved in eCB mediated short-term plasticity, the mechanism for eCB mediated
long-term plasticity involves the inhibition of AC (Lu & Mackie, 2016).
To facilitate eCB mediated synaptic plasticity, there are a variety of synthesis
pathways for both eCBs (Lu & Mackie, 2016). The best understood AEA synthesis
pathway involves the cleavage of the N-arachidonoyl phosphatidyl ethanol’s (NAPE)
phosphodiester bond by NAPE PLC, thereby removing a diacylglycerol (DAG) group to
produce phospho-AEA (Lu & Mackie, 2016). The phospho-AEA becomes
dephosphorylated by a phosphatase to synthesize and release AEA (Lu & Mackie, 2016).
In comparison to AEA, the main synthesis pathway for 2-AG begins with the hydrolysis
of arachidonoyl-containing phosphatidyl inositol bis-phosphate by PLC", thereby
removing inositol trisphosphate (Lu & Mackie, 2016). A second hydrolysis reaction of
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the DAG group by the enzyme diacylglycerol lipase (DAGL), removes a carboxyl group
to synthesize and release 2-AG (Lu & Mackie, 2016).
Once the eCBs are synthesized, both AEA and 2-AG can be catabolized by
cyclooxygenase-2 (COX-2) or fatty acid amide hydrolase (FAAH) (Lu & Mackie, 2016).
FAAH metabolizes various fatty acid amides, such as eCBs palmitoyl-ethanolamide
(PEA) and oleoyl-ethanolamide (OEA) (Lu & Mackie, 2016). Overall, the main catabolic
enzyme for AEA is FAAH, while the main catabolic enzyme for 2-AG is
monoacylglycerol lipase (MAGL) (Lu & Mackie, 2016). The enzymes involved in AEA
and 2-AG synthesis and catabolism are predominantly located in complementary neurons
in synapses (Hillard et al., 2018; Lu & Mackie, 2016; Morena, Patel, Bains, & Hill,
2016). AEA synthesis is facilitated by NAPE-PLD in presynaptic neurons and AEA
catabolism is facilitated by FAAH in postsynaptic neurons (Hillard et al., 2018; Lu &
Mackie, 2016; Morena et al., 2016). In comparison to AEA, 2-AG synthesis is facilitated
by DAGL in postsynaptic neurons and 2-AG catabolism is facilitated by MAGL in
presynaptic neurons (Hillard et al., 2018; Lu & Mackie, 2016; Morena et al., 2016).
These differences in enzyme locations in synapses contribute to AEA and 2-AG’s
complimentary functions in signaling (Hillard et al., 2018; Lu & Mackie, 2016; Morena
et al., 2016).
In addition to being synthesized and catabolized in opposite locations in synapses,
AEA and 2-AG have different pharmacodynamic effects on the CB receptors (Hillard et
al., 2018; Lu & Mackie, 2016; Morena et al., 2016). AEA has low efficacy for CB
receptors, so it is considered to be involved in tonic eCB signaling, while 2-AG has high
efficacy for CB receptors to facilitate phasic eCB signaling (Hillard et al., 2018; Lu &
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Mackie, 2016; Volkow et al., 2017). AEA also activates TRP channels and PPARs
(Hillard et al., 2018; Lu & Mackie, 2016). The lower efficacy of AEA constitutes it as a
partial agonist similarly to tetrahydrocannabinol (THC), a compound attributed to the
intoxicating effects cannabis (Volkow et al., 2017). Cannabidiol (CBD), is another wellresearched phytocannabinoid (i.e. from the cannabis plant) with non-psychoactive effects
(Morales & Reggio, 2019). CBD’s receptor pharmacology is complex (Morales &
Reggio, 2019). Functionally, CBD has been considered as an antagonist for CB receptors,
but recent research suggests that CBD could be a negative allosteric modulator (Morales
& Reggio, 2019). Furthermore, CBD inhibits FAAH, targets TRP channels, PPARs, and
many more targets whose functions have yet to be elucidated (Morales & Reggio, 2019).
Another relevant phytocannabinoid is "-Caryophyllene (BCP) which is a CB2R agonist
that is being investigated because of its anti-inflammatory effects (Hwang et al., 2020).
Like the wide variety of naturally occurring CB compounds, there are even more
synthetic CB compounds. One of the most infamous synthetic CBs is rimonabant (RIM),
which is a CB1R antagonist with inverse agonist effects when chronically administered
(Fang & Wang, 2018). Originally marketed for obesity, RIM was withdrawn in 2008 due
to psychiatric effects such as anxiety and suicidal ideation (Cinar, Iyer, & Kunos, 2020).
This instance was a grave lesson in understanding the direct relationship between CB1Rs
and mood in humans. Fortunately, the promising anti-obesity results in these trials has led
to the continuation of this research and current development of peripherally-restricted
CB1R antagonists for these metabolic disorders (Cinar et al., 2020). AM251, which is
structurally and pharmacologically similar to RIM, is another synthetic CB that is
frequently administered in preclinical behavioral experiments to block CB1R activity
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(Fang & Wang, 2018; Fogaça et al., 2018; McLaughlin et al., 2013; Pekala, Michalak,
Kruk-Slomka, Budzynska, & Biala, 2018; H.-n. Wang et al., 2014). Similarly, AM630, a
CB2R antagonist and inverse agonist, is used in preclinical behavioral experiments to
block CB2R activity (Fogaça et al., 2018; García-Gutiérrez et al., 2010; Ishiguro et al.,
2018).
Since THC is a Schedule I substance, a variety of synthetic CBs have been
developed to research the ECS (Leonhart, 2010). Commonly-researched, synthetic CBs
include WIN55,212-2, a CB1R and CB2R agonist, and HU-210, a potent non-selective
CB1R agonist (Hill & Gorzalka, 2004; Segev et al., 2014). More selective synthetic CBs
include, arachidonyl-2-chloro-ethylamide (ACEA), which is administered for CB1R
agonism, or JWH133 and JWH015, which are administered for CB2R agonism (Ishiguro
et al., 2018; S. Wang et al., 2016). In addition to targeting CB receptors, compounds
inhibiting catabolic enzymes FAAH and MAGL, which is intended to increase levels of
AEA and 2-AG respectively, have demonstrated greater clinical potential because they
increase CB signaling while circumventing receptor downregulation (Volkow et al.,
2017). The most popularly researched enzyme inhibitors are URB597 and JZL184 for
FAAH and MAGL, respectively (Ferizovic, Spasojevic, Stefanovic, Jankovic, &
Dronjak, 2020; Jankovic et al., 2020; Lomazzo et al., 2015; Lomazzo, Konig, Abassi,
Jelinek, & Lutz, 2017; Zhang et al., 2015; Zhong et al., 2014). Unfortunately, the clinical
development FAAH inhibitors was halted in 2016 due to a fatal phase I trial involving an
FAAH inhibiter called BIA 10-2474 (Volkow et al., 2017). The food and drug
administration safety review stated that the toxicity of BIA 10-2474 is unique to this
FAAH inhibitor (Volkow et al., 2017). BIA 10-2474’s toxicity is likely due to having a
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low affinity for FAAH thereby increasing the probability of off-target effects (Volkow et
al., 2017). Fortunately, the clinically safer FAAH inhibitors PF-04457845 and JNJ42165279 have currently resumed recruitment of participants for clinical research
(NCT03386487; NCT03664232). Although these compounds are being tested for a
variety of disorders, a substantial amount of the clinical trials for efficacy are focused on
stress-related psychopathologies.
Stress-Induced Endocannabinoid Mobilization
Chronic cannabis use appears to dysregulate the HPA axis (Hillard et al., 2018).
Therefore, it is possible that CBs can modulate the HPA axis (Hillard et al., 2018).
Evidence that supports the role of the ECS in both activating and terminating the HPA
axis begins with the expression of CB1R at all levels of the HPA axis (Hillard et al.,
2018). Hill and colleagues have hypothesized that AEA tonically inhibits the BLA by
basal CB1R activation and that the release of CRH activates CRHR1 to increase FAAH
activity, thereby reducing AEA levels to allow the BLA to facilitate activation of the
HPA axis (Hillard et al., 2018). Furthermore, mounting evidence supports the hypothesis
that GC release activates GR which mobilize the synthesis of eCBs to facilitate a rapid
nongenomic mechanism for negative feedback of the HPA axis (Hillard et al., 2018).
Although the specifics of this molecular mechanism has yet to be elucidated, evidence
suggests that GR-mediated increases in calcium and PLC activity are involved (Hillard et
al., 2018). In support of the GR-mobilization of eCB hypothesis, GC injections in the
PVN suggest that the release of 2-AG activates CB1R to reduce glutamatergic input onto
the PVN (Hillard et al., 2018). Additional evidence to support this hypothesis involve
GR-mediated mobilization of 2-AG in the PFC and hippocampus (Hillard et al., 2018). 2-
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AG would activate CB1R to reduce GABAergic input into the PFC and hippocampus,
thereby disinhibiting these regions in order to facilitate negative feedback of the HPA
axis (Hillard et al., 2018). These hypotheses suggest that eCB signaling facilitates an
adaptive stress response, demonstrated in the rapid and effective activation of the HPA
axis followed by a timely and complete termination of the HPA axis (Franklin et al.,
2012; Hillard et al., 2018). Based on these hypotheses, researchers hope to invent novel
pharmacotherapies that reliably enhance eCB signaling in order to regulate the HPA axis
and protect against stress-related psychopathologies (Hillard et al., 2018).
Statement of the Problem
Based on the role of the ECS in both activation and termination of the HPA axis,
exogenous administration of CBs have the potential to both dysregulate and regulate the
HPA axis (Hillard et al., 2018). The purpose of the present study is to better understand
the conditions in which exogenous administration of CBs promote stress vulnerability
and the conditions in which exogenous administration of CBs promote stress resilience
with a systematic review and meta-analysis. Therefore, the proposed categorical
moderators of this meta-analysis are species (rats vs. mice), sex (males vs. females),
strain (control strain vs. disease model), method of administration (systemic vs. sitespecific), timing of administration relative to CUS (before vs. during vs. after), and
overall effect on the ECS (enhancement vs. inhibition vs. neutral). The proposed
continuous moderators are dose of the CB, number of administrations, and days of stress.
It is hypothesized that CBs would be most effective at promoting stress resilience
in females and in disease models. The stress-resilient effects of CBs would be greatest in
the most severe CUS models (i.e. with the longest duration). Furthermore, the most
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efficacious CBs would be those that enhance the ECS when they are administered
systemically at low doses during CUS. The stress-resilient effect of CBs would also be
easier to sustain with CBs that target catabolic enzymes than with CBs that target CB
receptors due to receptor regulation (i.e. tolerance). In contrast, high doses of CBs for
short periods of time or chronic administration of CBs that inhibit the ECS are
hypothesized to promote stress vulnerability.
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CHAPTER III
MATERIALS AND METHODS
Overview
This research adheres to the CAMRADES guidelines for conducting systematic
reviews and meta-analysis of animal studies (Vesterinen et al., 2014). The preregistered
research protocol in the Systematic Review Protocol for Animal Intervention Studies
(SYRCLE) format is located in the appendix of this thesis (R. B. M. de Vries et al., 2015;
Hooijmans et al., 2014). Duplicates of this protocol are publicly available in the
Systematic Review Facility (SyRF) protocol database, PROSPERO protocol database
(registration number: CRD42020219986), and on the Open Science Framework
(https://osf.io/csgmf/) in order to facilitate visibility and transparency (R. B. M. de Vries
et al., 2015). These resources were originally found in Reis, Casteen, and Ilardi’s
preclinical systematic review and meta-analysis (Reis, Casteen, & Ilardi, 2019).
Furthermore, additional resources to facilitate transparency were obtained from Moreau
and Gamble and will be cited accordingly (Moreau & Gamble, 2020).
Criteria
Articles were deemed eligible for the meta-analysis if they met the following
inclusion criteria: 1) study subjects were either rats or mice (R. B. de Vries, Hooijmans,
Tillema, Leenaars, & Ritskes-Hoitinga, 2014; Hooijmans, Tillema, Leenaars, & RitskesHoitinga, 2010; Leenaars et al., 2012); 2) subjects received administration of a CB; 3)
outcome measures included behavioral and/or neuroendocrinological stress; 4) subjects
were exposed to variable heterotypic stressors for more than seven days; 5) there was a
study matched control group; 6) the article was the primary source of the research (i.e.
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not a review); 7) the article was available in English. Although this last criteria poses as
an inherent bias against non-English articles, there appears to be minimal benefit in the
translation of non-English articles (Jüni, Holenstein, Sterne, Bartlett, & Egger, 2002).
Conference abstracts were omitted due to limited information. In the second stage of
screening, the reason for removal of the article was documented and reported (Figure 1)
in order facilitate transparency of the screening process (Leenaars et al., 2012). The
inclusion criterion of “variable heterotypic stressors for more than seven days” was
applied in the second stage of screening in order to prioritize severe and previously
validated CUS paradigms. Protocol deviations such as these were documented and are
located in the appendix of this thesis (Table 5).
Search Strategy
Potential articles were identified by searching Scopus, Embase, Psychology &
Behavioral Sciences Collection, APA PsychINFO, PubMed, CINAHL Complete, and
ProQuest Dissertations & Theses Global from the earliest record of the databases to
November 2020. The libraries were imported into EndNote X9 and Mendeley for
automatic then manual de-duplication which was replicated at least three separate times
to ensure that no reference was deleted by accident. Search terms included rat OR mouse
AND cannabinoids AND chronic stress. The complete search strategy including the exact
search syntax used for each database is located in the appendix of this thesis (Table 6).
All articles were screened and evaluated in a standardized manner by two independent
reviewers (N.R. and C.C). First, the title and abstract for each reference was reviewed to
identify potential articles before reviewing the full-text to determine article eligibility.
Disagreements between reviewers were resolved by discussion and the final decision was
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made by a third independent reviewer (S.F.). In included articles, citations were tracked
both forwards and backwards to search for additional articles. Both forms of citation
tracking did not result in additional included articles, indicating that there was no need
for further citation tracking of excluded reviews. Authors of included studies, relevant
investigators at the National Institute of Health, and at the Hebrew University
Multidisciplinary Center on Cannabinoid Research were contacted for grey literature. In
total, 53 authors were individually contacted for grey literature in efforts to include all
relevant data. Thirteen of those 53 emails received a response, and two of those responses
contained article suggestions that were later excluded. Finally, authors of included studies
were contacted and asked to provide additional study details and data when needed.
Twenty-nine additional emails were sent out to request additional information. Out of
those 29 additional emails, two responded saying they did not have the requested
information, one agreed to send their data but was unable to find it, and one researcher
responded with a raw dataset that corresponded to an included article. This raw dataset
was used for a validation analysis by comparing the raw dataset to data extracted by the
two independent reviewers using the WebPlotDigitizer software (Rohatgi, 2017). After
the validation analysis, the raw dataset was used for the meta-analysis instead of the
reviewer-extracted data. An additional exploratory search was conducted based on article
recommendations provided by the Mendeley reference manager software, which yielded
36 additional articles that were later excluded.
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Other Sources (n = 9)

Search

Electronic Databases (n = 1,711)
Searching electronic databases (Psychology and Behavioral
Sciences Collection (n = 20), APA PsychINFO (n = 285),
CINAHL Complete (n = 42), PubMed (n = 534), SCOPUS (n =
400), and EMBASE (n = 430)) using combinations of search
terms relating to RATS OR MICE AND CANNABINOIDS AND
CHRONIC UNPREDICTABLE STRESS (Table 6 shows a full list of
search terms).

ProQuest Dissertations & Theses Global (n = 9),
open call e-mail requests for unpublished data (n =
0), forwards citation tracking using Google Scholar
of Included Articles (n = 0) and backwards citation
tracking of Included Articles (n = 0).

Records After Duplicates Removed
(n = 714)

Inclusion Criteria

Criteria For Study Inclusion
Inclusion Criteria
1. Article text available in English
2. Subjects are rats or mice
3. Administration of a cannabinoid (e.g. WIN55,212-2)
4. Outcome data related to anxiety tests (e.g. Open Field test) or stress-coping behaviors (e.g. Self-Grooming) and/or
accompanying biochemical data (e.g. related to the endogenous cannabinoid system or hypothalamic pituitary
adrenal axis stress response)
5. Chronic Unpredictable Stress (i.e. variable stress is administered for more than seven days).
6. Control group (i.e. vehicle administration)
7. Primary Research

Abstracts Excluded (n = 490)

Eligibility

Abstracts Screened
(n = 714)

Full Text Articles Evaluated but Excluded (n = 188)

Full Text Articles
Evaluated for
Eligibility
(n = 35)

Included

Full Text Articles Unobtainable (in English) (n = 2)

1.
2.
3.
4.
5.

6.
7.

Article text available in English (n = 0)
Subjects are rats or mice (n = 11)
Administration of a cannabinoid (n = 10)
Outcome data (n = 14)
Chronic Stress (n – 75)
subChronic Unpredictable Stress (n = 18)
subChronic Homotypic Stress (n = 27)
Chronic Homotypic Stress (n = 31)
Control group (n = 0)
Primary Research (n = 2)

Articles Included (n = 26)
35 Study Groups • 165 Effect Sizes

Figure 1. Flowchart of the Selection of Articles. Adapted from Moreau, D., & Gamble, B.
(2020, January 7). Conducting a Meta-Analysis in the Age of Open Science: Tools, Tips,
and Practical Recommendations. https://doi.org/10.31234/osf.io/t5dwg
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Data Collection
All coding was completed using an online custom REDCap form that was
developed based on CAMRADES guidelines (Harris et al., 2009; Vesterinen et al., 2014).
For a complete list of extracted data fields, the REDCap codebook file is attached to the
publicly available registered protocol in the SyRF protocol database, PROSPERO
protocol database (registration number: CRD42020219986), and on the Open Science
Framework (https://osf.io/csgmf/). Extracted data included subject information (e.g.
rodent species, strain, age, and model), housing information (e.g. temperature and
humidity), intervention type (e.g. frequency of stressors, number of stressors, and
disruption of circadian rhythm), injection information (e.g. method of administration,
dosage, and timing relative to stress), drug preparation (e.g. solvent), CB pharmacology
(e.g. target) as well as behavioral data (e.g. sucrose preference and forced swim
immobility time). Neuroendocrinological data from the articles included in the metaanalysis was collected for systematic review due to anticipated limitations in sample size.
Data presented in graphical format was extracted using WebPlotDigitizer graph
digitization software (Rohatgi, 2017). A validation analysis compared the raw dataset
provided from the researcher that responded, to the data that was extracted by the two
independent reviewers using the WebPlotDigitizer software (Rohatgi, 2017). The means
of the extracted dataset were within 3% of the raw dataset, while the standard errors of
the means of the extracted dataset were within 13% of the raw dataset. If the final group
sizes were given in a range, then the lowest number within that range was collected for a
conservative estimate. Twenty-one articles used the standard error of the means for the
error bars in their figures, and one article used standard deviation. Therefore, the four
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articles which did not specify their error bars were assumed to be standard error of the
mean. Unfortunately, this limitation in reporting variance has been previously observed
in preclinical research (Vesterinen et al., 2014). Finally, for studies with repeated
measures, data was only collected for the last measurement. All forms of data collection
were conducted by two independent reviewers (N.R. and C.C). Disagreements between
reviewers on article characteristics and neuroendocrinological data were resolved by
discussion, and the final decision was made by a third independent reviewer (S.F.). For
the behavioral data, measurements that were not within half a unit of each other or within
one unit of each other for the novelty suppressed feeding test were recalculated by both
independent reviewers until they were within said range, then averaged. The standardized
mean difference (SMD) calculations between both independent reviewers were also
confirmed to be within 0.05 of each other.
Quality Assessment
Potential bias was evaluated using a modified version of SYRCLE’s risk-of-bias
tool (Hooijmans et al., 2014). SYRCLES’s risk-of-bias tool was adapted to include four
additional evaluation measures: control for the locomotor effects of CBs, sample size
calculations, conflict of interest statements, and proper vehicle administration (Macleod
et al., 2015). Risk-of-bias evaluations were conducted by two independent reviewers
(N.R. and C.C). Disagreements between reviewers on risk-of-bias evaluations were
resolved by discussion, and the final decision was made by a third independent reviewer
(S.F.).
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20 Laboratories

26 Articles

35 Study Groups (70 Measurement Type Studies)

Anhedonia
(14 Studies)
18 Control
Groups
29 Effect Sizes

Learned
Helplessness
(19 Studies)
27 Control
Groups
49 Effect Sizes

Novelty
Suppressed
Feeding
(10 Studies)
13 Control
Groups
21 Effect Sizes

Time Spent in
the Anxiogenic
Context
(17 Studies)
21 Control
Groups
39 Effect Sizes

Entries Into the
Anxiogenic
Context
(10 Studies)
13 Control
Groups
27 Effect Sizes

92 Control Groups

165 Effect Sizes

Figure 2. Levels of Dependencies. Five levels of dependencies identified in the metaanalysis. The main mixed effect model is a multilevel model nesting the effect sizes
within measurement type studies, study groups, and articles. Furthermore, the effect size
weights are nested within control groups.
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CHAPTER IV
DATA ANALYSIS
Statistical Analysis
The meta-analysis was performed using the metaphor package in R (v4.0.2)
software (RCoreTeam, 2020; Viechtbauer, 2010). Although all behavioral and
neuroendocrinological measures were collected, meta-analyses were conducted for the
most common behavioral measures in the interest of statistical power. A random effects
model was used to account for the variance due to methanological heterogeneity and a
multilevel model was used to model dependencies between articles, study groups, and
measurement type studies (Vesterinen et al., 2014).
In the present study, five levels of dependencies were identified: laboratories,
articles, study groups, measurement type studies, and control groups. At the laboratory
level, research is usually published from a similar group of investigators sharing the same
equipment. The laboratory level was the only level of dependency that was not able to be
addressed by the multilevel model since the remaining levels were prioritized as greater
sources of dependencies. Laboratory level dependency can overlap with article level
dependency. Examples of laboratory and article level dependencies include shared
subject pools, protocols, and analysis methods (Tipton, 2015). At the study level, a single
article can consist of multiple correlated studies sharing similar research designs
(Vesterinen et al., 2014). At the measurement type level, the same group of subjects can
be used for multiple tests and multiple different measurements can be collected from the
same test (Vesterinen et al., 2014). At the control group level, the same measurements
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from multiple experimental groups are compared to the same control group (Vesterinen et
al., 2014).
For continuous measures of stress-coping behaviors (e.g. immobility time in
seconds in a forced swim test), a SMD for vehicle CUS and CB-treated CUS groups was
calculated. The SMD, also known as Hedge’s G is similar to Cohen’s D because they
both utilize a pooled standard deviation (Lakens, 2013). Hedge’s G is usually preferred in
meta-analyses because this effect size corrects for biases in small sample sizes (Lakens,
2013; Vesterinen et al., 2014). A restricted maximum likelihood estimate method was
used in the models to avoid underestimation of the variance or bias in the estimation of
variance (Vesterinen et al., 2014). Categorical moderators of this meta-analysis were
species (rats vs. mice), method of administration (systemic vs. site-specific), timing of
administration relative to CUS (before vs. after vs. both), overall effect on the ECS
(enhancement vs. inhibition vs. neutral) and co-administration (yes vs. no). Continuous
moderators were dose of the CB, number of administrations, and days of stress. In one
article, days of stress were given in a range, so the lowest value was used for a
conservative estimate (García-Gutiérrez et al., 2010). For the two articles that
administered CBs every two days, the number of administrations was counted by
assuming that the first administration began on the first day (Zhang et al., 2015; Zhong et
al., 2014). There was no missing moderator data. However, it is important to note that
there were not enough effect sizes to be able to conduct two proposed moderator analyses
for the effects of model (control vs. disease) and sex (males vs. females) with three effect
sizes for disease models and four effect sizes for females.
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Separate subgroup meta-analyses were also conducted for each test measurement
as an additional method to address measurement type study level dependency. To address
control group level dependency, if there were multiple different CB-treated CUS groups
compared to a single vehicle CUS group, the SMD was calculated for each group, and a
nested weight (based on precision which is regarded as the inverse of variance) was
created so that every effect size compared to the same control group shared the same
weight. This nested control group weight allowed for separate SMD measurements while
addressing dependency between measurements with the same control group.
Potential publication bias from funnel plot asymmetry was assessed using Egger
regression (Egger, Smith, Schneider, & Minder, 1997). Between-study and within-study
heterogeneity was evaluated using the # % statistic with # % of more than 25%, 50%, and
75% selected to reflect low, moderate, and high heterogeneity respectively (Higgins,
Thompson, Deeks, & Altman, 2003).
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CHAPTER V
RESULTS
Article Selection and Characteristics
This meta-analysis contains 26 articles from 20 independent laboratory groups.
From these articles, there are 35 study groups, producing a total of 70 measurement type
studies for all five test measurements: 1) anhedonia; 2) learned helplessness; 3) novelty
suppressed feeding; 4) time spent in the anxiogenic context; 5) entries into the anxiogenic
context. These five meta-analyses are composed of 165 effect sizes (Figure 2). Twelve
articles used rats as experimental subjects and 14 articles used mice.
The stress schedule was between ten to 73 days with one to four stressors per day
for an average of 34 days of stress (Table 1). Subjects received between four to 17
different types of stressors, with the most common stressors being “food and/or water
deprivation” and “wet bedding or water” each accounting for 12% of the total types of
stressors administered (Table 2). Aside from CBs, compounds targeting serotonin
receptors or reuptake (i.e. WAY100635 and sertraline, respectively) and nicotinic
acetylcholine receptors (i.e. nicotine) were administered in three articles but were all able
to be controlled for with a corresponding study matched control group (Buran, Etem,
Tektemur, & Elyas, 2017; Fogaça et al., 2018; Pekala et al., 2018; Vesterinen et al.,
2014). Additional treatments include repetitive transcranial magnetic simulation (rTMS),
which was controlled for in one of the two articles (H.-n. Wang et al., 2014). In the other
article, there was one study where rTMS was administered to both the vehicle CUS and
CB-treated CUS groups and therefore could not be controlled for (Fang & Wang, 2018).
The effect sizes from this article were kept in the meta-analysis and addressed in the co-
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treatment moderator analysis as co-treatments (Fang & Wang, 2018). Finally, one article
conducted an additional treatment of a middle cerebral artery occlusion surgery that could
not be controlled for because the surgery was performed on all CUS subjects (S. Wang et
al., 2016). This article was kept in the meta-analysis and this additional intervention was
addressed by adding a “high” evaluation score to be factored into the bias score for the
sensitivity analysis (Table 7) (Reis et al., 2019; S. Wang et al., 2016).
The most common method of administration was intraperitoneal injection, with
21 out of 26 articles containing studies in which CBs were administered through
intraperitoneal injections. In three studies, CBs were administered orally (Griebel,
Stemmelin, & Scatton, 2005; Jin et al., 2015; Xu et al., 2019). In one study the AEA was
administered subcutaneously, and in another study the CBD was administered
intravenously (Buran et al., 2017; Xu et al., 2019). In four studies, CBs were
administered intracranially to the hippocampus (CA1), PFC, BLA, and ventral medial
hypothalamus (VMH) after CUS (Fang & Wang, 2018; McLaughlin et al., 2013; Segev et
al., 2014; S. Wang et al., 2016). In addition to these four studies, there were five other
studies in which CBs were administered after CUS, for a total of nine studies. In
comparison, the most common administration schedule was during CUS, with 19 articles
containing studies in which CBs were administered during CUS (and two articles with
studies in which CB administration continued a few days after CUS).
CBs were administered between one and 56 times. Fifteen articles administered
their CB daily. Three articles administered their CB’s twice daily (Ferizovic et al., 2020;
García-Gutiérrez et al., 2010; Jankovic et al., 2020). Two articles administered JZL184
every two days (Zhang et al., 2015; Zhong et al., 2014). One article administered CBD
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weekly (Xu et al., 2019). Only one study used a disease model (i.e. glial fibrillary acidic
protein thymidine kinase transgenic mice) and two articles from the same laboratory used
female subjects (Campos et al., 2013; Ferizovic et al., 2020; Jankovic et al., 2020).

Author, year

Subjects

Bortolato et al., 2007

200g Male Wistar Rats

Buran, Etem, Tektemur, &
Elyas, 2017
Campos et al., 2013
Fang & Wang, 2018
Ferizovic, Spasojevic,
Stefanovic, Jankovic, &
Dronjak, 2020
Fogaça, Campos, Coelho,
Duman, & Guimarães,
2018
Fokos & Panagis (2010)
Gall et al., 2020
García-Gutiérrez, PérezOrtiz, Gutiérrez-Adán, &
Manzanares, 2010
Griebel, Stemmelin, &
Scatton, 2005
Hill & Gorzalka, 2004
Hwang et al., 2020
Ishiguro et al., 2018
Jankovic, Spasojevic,
Ferizovic, Stefanovic, &
Dronjak, 2020
Jin, Yu, Tian, Zhang, &
Quan, 2015
Lomazzo et al., 2015
Lomazzo, Köing, Abassi,
Jelinek, & Lutz, 2017
McLaughlin et al., 2013
Onaivi et al., 2008
Pekala, Michalak, KrukSlomka, Budzynska, &
Biala, 2018

Stress
Types
9

Treatment(s)

Administration Schedule

URB597 0.03, 0.1, and 0.3 mg/kg (i.p.)

Daily - last 35 days of CUS (35 total)

40g Male BALB/c Mice (90 days
old)
Male GFAP-TK and C57BL/6J
Mice (90 days old)
Male Sprague Dawley Rats (21
days old)
250-300g Male and Female Wistar
Rats (77 days old)

Stress
Schedule
70 days
(2-3/day)
49 days
(2-3/day)
14 days
(1/day)
21 days
(2-3/day)
42 days
(2/day)

11

AEA 5 mg/kg (s.c.) and Sertraline 10 mg/kg (i.p.)

After CUS (3 total)

6

CBD 30 mg/kg (i.p.) and AM251 1 mg/kg (i.p.)

Daily - Concurrent with CUS (14 total)

8

rTMS and AM251 1 mg/kg (i.p.) or 0.35 ng/0.5𝜇l/side
(intra-CA1)
URB597 0.3 mg/kg (i.p.)

Daily - 7 days after CUS (7 total)

20-26g Male C57BL/6J Mice (5663 days old)

14 days
(1/day)

8

CBD 30 mg/kg (i.p.), AM251 0.3 mg/kg (i.p.), AM630
0.3 mg/kg (i.p.), and WAY100635 0.05 mg/kg (i.p.)

Daily - Concurrent with CUS (14 total)

270-320g Male Sprague Dawley
Rats
355-419g Adult Male Wistar Rats

10 days
(2/day)
28
(2/day)
49-56
days (13/day)
49 days
(1-3/day)
21
(3/day)
28 days
(1-2/day)
14
(2/day)
42 days
(2/day)

7

THC 0.5 and 1 mg/kg (i.p.)

After CUS (1 total)

11

CBD 10 mg/kg (i.p.)

7

AM630 1 mg/kg (i.p.)

Daily - Concurrent with CUS and 4 days
after (32 total)
Twice daily - last 28 days of CUS (56
total)

4

Rimonabant 10 mg/kg (p.o.)

Daily - last 35 days of CUS (35 total)

6

HU-210 10 and 50 𝜇g/kg (i.p.)

After CUS (1 total)

4

𝛽-Caryophyllene 25, 50, and 100 mg/kg (i.p.)

Daily - Concurrent with CUS (28 total)

6

AM630 3 mg/kg (i.p.) and JWH015 20 mg/kg (i.p.)

Daily - Concurrent with CUS (14 total)

13

URB597 0.3 mg/kg (i.p.)

Twice daily - last 14 days of CUS (28
total)

28 days
(2/day)
73 days
(2-3/day)
73 days
(2-3/day)
21 days
(2-3/day)
28 days
27 days
(1/day)

14

Oleoylethanolamide 1.5, 3, 6 mg/kg (p.o.)

Daily - last 21 days of stress (21 total)

17

URB597 1 mg/kg (i.p.) and JZL184 8 mg/kg (i.p.)

Daily - last 38 days of stress (38 total)

17

URB597 1 mg/kg (i.p.)

Daily - last 38 days of stress (38 total)

8

AM251 0.28 ng/0.2𝜇l/side (intra-vmPFC)

After CUS (1 total)

6
7

JWH015 20 mg/kg (i.p.) and AM630 1 and 3 mg/kg (i.p.)
Nicotine 0.1 and 0.2 mg/kg (s.c.), Oleoylethanolamide
2.5 mg/kg (i.p.), AM251 0.25 mg/kg (i.p.), JWH133 2
mg/kg (i.p.), and AM630 2 mg/kg (i.p.)

Daily - Concurrent with CUS (28 total)
After CUS (1 total)

25-35g Male Swiss ICR Mice (6090 days old)
20-27g Male BALB/c Mice
300g Male Long Evans Rats (70
days old)
167-183g Male Sprague Dawley
Rats (49 days old)
20-25g Male C57BL/6J Mice (5670 days old)
250-300g Male and Female Wistar
Rats (77 days old)
18-22g Adult Male Kunming Mice
Male C57BL/6J Mice (42 days old)
Male C57BL/6J Mice (42 days old)
300g Male Sprague Dawley Rats
(70 days old)
Male and Female BALB/c Mice
20-25g Male Swiss Mice (60 days
old)

13

Twice daily - last 14 days of CUS (28
total)

Table 1. Article Characteristics. CUS – Chronic unpredictable stress, GFAP-TK – glial fibrillary acidic protein thymidine kinase
transgenic mice, AEA- Anandamide, CBD – Cannabidiol, rTMS – repetitive transcranial magnetic simulation, THC tetrahydrocannabinol, i.p. – intraperitoneal, s.c. – subcutaneous, p.o. – oral, CA1 – first region in the hippocampus, vmPFC –
ventromedial prefrontal cortex.
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Author, year

Subjects

Segev, Rubin, Abush,
Richter-Levin, & Akirav,
2014
Wang et al., 2014

Male Sprague Dawley Rats (45
days old)

Wang et al., 2016
Xu et al., 2015
Zhang et al., 2015
Zhong et al., 2014

Stress
Schedule
21 days
(1-2/day)

Stress
Types
8

Treatment(s)

Administration Schedule

WIN55,212-2 0.5 mg/kg (i.p.) and 5𝜇g/0.5𝜇l/side (intraBLA)

Daily - last 3 days of CUS (i.p. 3 total);
After CUS (intra-BLA 1 total)

180-230g Male Sprague Dawley
Adult Rats
250-270g Male Sprague Dawley
Adult Rats

28 days
(1-4/day)
18 days

14

rTMS and AM251 1 mg/kg (i.p.)

Daily - 7 days after CUS (7 total)

9

Daily - first 7 days of CUS (i.p. 7 total) ;
After CUS (intra-VMH 1 total)

32-38g Male ICR Mice (42 days
old)
Male C57BL/6J Mice (56-70 days
old)
17-25g Male C57BL/6J Mice (5670 days old)

35 days

4

Middle cerebral artery occlusion surgery, ACEA 1 and 10
(i.p.) or 0.2 and 2 𝜇g/0.5𝜇l/side (intra-VMH), JWH133 1
and 5 mg/kg (i.p.) or 0.3 and 3 𝜇g/0.5𝜇l/side (intra-VMH)
CBD 10 (i.v.), 10, and 100 (p.o.)

35 days
(1-2/day)
35 days
(2/day)

11

JZL184 8 mg/kg (i.p.)

11

JZL184 8 mg/kg (i.p.) and Rimonabant 2 mg/kg (i.p.)

Every two days - last 14 days of stress and
7 days after (11 total)
Every two days - 21 days of CUS and 7
days later (14 total); Every two days - last
day of CUS and 7 days later (4 total)

Weekly - last 28 days of CUS (4 total)

Table 1. Article Characteristics (continued). CUS – Chronic unpredictable stress, rTMS – repetitive transcranial magnetic simulation,
CBD – Cannabidiol, ACEA - Arachidonyl-2-chloroethylamide, i.p. – intraperitoneal, p.o. – oral, i.v. – intravenous, BLA – basolateral
amygdala, VMH – ventral medial hypothalamus.
Stressor
Light and Circadian Rhythm
Stroboscopic Light Flashes
Modified Light Dark Cycle
Housing
Tilted Cage
Repeated Cage Changing
Removal of Bedding
Wet Bedding or Water
Social
Isolation
Crowding or Other
Environmental
Auditory
Temperature (Hot or Cold)
Foreign Object or Odor
Oscillation or Forced Running
Restraint or Immobilization
Food and/or Water Deprivation
Forced Swimming Test
Pain (Tail Suspension Test, Tail Pinch, or Foot Shock)

%
16
7
9
29
10
2
5
12
11.5
4
7.5
15.5
5.5
5
3
2
8
12
5
3

Table 2. Stress Types. Proportion of stress types used across articles.
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Neuroendocrinological Results
Cannabinoid-Related Effects
All CB-related measurements between the vehicle CUS and CB-treated CUS
groups were included in Table 3. CBD at a dose of 30 mg/kg inhibits and significantly
reduces FAAH expression in the hippocampus, while URB597 at dose of 0.3 mg/kg
inhibits and significantly reduces FAAH expression in the striatum, midbrain, and
hippocampus (Bortolato et al., 2007; Fogaça et al., 2018). Complimentary to these
effects, URB597 at dose of 1 mg/kg significantly increases AEA and PEA levels in the
cingulate, PFC, hypothalamus, and midbrain (Lomazzo et al., 2015). In the midbrain,
URB597 at dose of 0.3 mg/kg significantly increases levels of OEA (in addition to AEA
and PEA) and decreases CB1R expression (Bortolato et al., 2007; Lomazzo et al., 2015).
Finally, AM630 at a dose of 1 mg/kg and BCP at a dose of 25 and 50 mg/kg (but not 100
mg/kg) increase CB2R genetic and protein expression, respectively, compared to their
vehicle CUS groups (García-Gutiérrez et al., 2010; Hwang et al., 2020).
Stress-Related Effects
Only the most common measurements between the vehicle CUS vehicle and CBtreated CUS groups were included in the interest of creating a cohesive overview (Table
4). A complete table is available on the Open Science Framework (https://osf.io/csgmf/).
It is important to also mention two articles which measured hormone levels. In one
article, rat hair CORT was measured before and after CUS (Gáll et al., 2020). In the
vehicle group, CUS significantly reduced CORT levels, and in the CBD group, CUS
slightly increased CORT levels (Gáll et al., 2020). Gáll and colleagues hypothesize that
this decrease in CORT levels in the vehicle CUS group reflects HPA axis hypofunction
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that was prevented by CBD treatment (Gáll et al., 2020). In the other article, OEA
administered at a dose of 6 mg/kg (but not 1.5 or 3 mg/kg) during CUS significantly
reduced serum ACTH and CORT levels compared to the vehicle CUS group (Jin et al.,
2015). Furthermore, OEA administered at a dose of 6 mg/kg (but not 1.5 or 3 mg/kg)
during CUS significantly reduced the adrenal index (measured as the bilateral adrenals
weights / body weight) compared to the vehicle CUS group (Jin et al., 2015). Both
articles measuring hormone levels support the notion that CB administration prevents
HPA axis dysregulation, demonstrated by hormone levels that are more comparable to
non-stressed group or measure.

Brain Region
Cingulate

Measure
LC-MRM

Cingulate

qRT-PCR
ChIP
Double in situ
LC-MRM

PFC

PFC
Thalamus
Hypothalamus

Striatum
Midbrain

LC-MS
qRT-PCR
LC-MS
LC-MRM

LC-MS
FAAH Assay
LC-MS
FAAH Assay
qRT-PCR

Midbrain

LC-MRM

Hippocampus
Hippocampus

LC-MS
FAAH Assay
qRT-PCR
Western Blot

Hippocampus

LC-MRM

Hippocampus

qRT-PCR

Hippocampus

Western Blot

Treatment
URB597 1 mg/kg and URB597 + JZL184
JZL184 8 mg/kg
JZL184 8 mg/kg and URB597 + JZL184
URB597 1 mg/kg
URB597 1 mg/kg

URB597 0.3 and 0.1 mg/kg
URB597 0.03 mg/kg
URB597 1 mg/kg and URB597 + JZL184
JZL184 8 mg/kg
JZL184 8 mg/kg and URB597 + JZL184
URB597 1 mg/kg
URB597 0.1, 0.03, and 0.3 mg/kg
URB597 0.3 mg/kg
URB597 0.3 mg/kg
CBD 30 mg/kg

Expression
↑ AEA and PEA
↔ AEA and PEA
↑ 2-AG
↔ 2-AG
↔ CB1R, FAAH, and MAGL
↔ CB1-H3K9ac and CB1-H4K8ac
↔ CB1 on 𝐺𝐴𝐷65+ and 𝐺𝐴𝐷65−neurons
↑AEA and PEA
↔ AEA and PEA
↑ 2-AG
↔ 2-AG
↔ AEA
↓ CB1R
↑ AEA; ↔ AEA
↑ AEA and PEA
↔ AEA and PEA
↑ 2-AG
↔ 2-AG
↑ AEA; ↔ AEA
↓ FAAH
↑ AEA; ↔ AEA
↓ FAAH
↓ CB1R
↑ OEA and PEA
↔ OEA and PEA
↑AEA and PEA
↔ AEA and PEA
↑ 2-AG
↔ 2-AG
↔ AEA
↓ FAAH
↔ CB1R
↓ FAAH

URB597 1 mg/kg and URB597 + JZL184
JZL184 8 mg/kg
JZL184 8 mg/kg and URB597 + JZL184
URB597 1 mg/kg
AM630 1 mg/kg

↔ AEA and ↑PEA
↔ AEA and PEA
↑ 2-AG
↔ 2-AG
↑ CB2R

𝛽-caryophyllene 25 and 50 mg/kg
100 mg/kg

↑ CB2R
↔ CB2R

URB597 1 mg/kg and URB597 + JZL184
JZL184 8 mg/kg
JZL184 8 mg/kg and URB597 + JZL184
URB597 1 mg/kg
URB597 0.1, 0.03, and 0.3 mg/kg
URB597 0.3 mg/kg
URB597 0.3; 0.1 and 0.03 mg/kg
URB597 1 mg/kg and URB597 + JZL184
JZL184 8 mg/kg
JZL184 8 mg/kg and URB597 + JZL184
URB597 1 mg/kg
URB597 0.3; 0.1 and 0.03 mg/kg
URB597 0.3 mg/kg
URB597 0.3; 0.1 and 0.03 mg/kg
URB597 0.3 mg/kg

Subjects
Male C57BL/6J Mice (42
days old)

Author, year
Lomazzo et al., 2015

Male C57BL/6J Mice (42
days old)

Lomazzo, Köing, Abassi, Jelinek, &
Lutz, 2017

Male C57BL/6J Mice (42
days old)

Lomazzo et al., 2015

200g Male Wistar Rats

Bortolato et al., 2007

200g Male Wistar Rats
Male C57BL/6J Mice (42
days old)

Bortolato et al., 2007
Lomazzo et al., 2015

200g Male Wistar Rats

Bortolato et al., 2007

200g Male Wistar Rats

Bortolato et al., 2007

Male C57BL/6J Mice (42
days old)

Lomazzo et al., 2015

200g Male Wistar Rats

Bortolato et al., 2007

20-26g Male C57BL/6J
Mice (56-63 days old)
Male C57BL/6J Mice (42
days old)

Fogaça, Campos, Coelho, Duman, &
Guimarães, 2018
Lomazzo et al., 2015

25-35g Male Swiss ICR
Mice (60-90 days old)
167-183g Male Sprague
Dawley Rats (49 days old)

García-Gutiérrez, Pérez-Ortiz,
Gutiérrez-Adán, & Manzanares, 2010
Hwang et al., 2020

Table 3. Cannabinoid-Related Effects. ↓ and ↑ represent a statistically significant decrease or increase (respectively) while ↔
represents a non-significant or unclear change. Drug doses are administered intraperitoneally and consistent within the article unless
stated otherwise. LC-MRM – liquid chromatography multiple reaction monitoring, qRT-PCR - quantitative real time polymerase
chain reaction, ChIP – chromatin immunoprecipitation, double in situ – double in situ hybridization, LC-MS – liquid chromatography
mass spectrometry, FAAH – fatty acid amide hydrolase, CBD – Cannabidiol, AEA – anandamide, PEA – palmitoyl-ethanolamide,
OEA – oleoyl-ethanolamide, 2-AG – 2-arachydonylglycerol, MAGL – monoacylglycerol lipase, CB1/CB1R – cannabinoid 1 receptor,
CB2R – cannabinoid 2 receptor H3K9ac – histone 3 lysine 9 acetylation H4K8ac – histone 4 lysine 8 acetylation, GAD65 – glutamic
acid decarboxylase 65 kilodalton.
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Brain Region
mPFC

Measure
ELISA

Treatment
Oleoyl-ethanolamide 1.5, 3 and 6 mg/kg p.o.

Expression
↑ BDNF

PFC

qRT-PCR

Hippocampus

ELISA

CBD 100 mg/kg p.o. and 10 mg/kg i.v.
CBD 10 mg/kg p.o.
Oleoyl-ethanolamide 1.5, 3 and 6 mg/kg p.o.

↑ BDNF
↔ BDNF
↑ BDNF

Hippocampus

qRT-PCR

CBD 10 mg/kg p.o., 100 mg/kg p.o., and 10 mg/kg i.v.

↔ BDNF

Hippocampus

Western Blot

𝛽-caryophyllene 25, 50 and 100 mg/kg

↑BDNF

Hippocampus

qRT-PCR
IHC
Western blot

AM630 1 mg/kg

↔BDNF (increased trend)
↔BDNF
↓ BDNF
↔ BDNF
↓ 𝐵𝑟𝑑𝑈 +cells
↔ 𝐵𝑟𝑑𝑈 +cells
↑ 𝐵𝑟𝑑𝑈 +cells
↑ 𝐷𝐶𝑋 + cells
↑ 𝐷𝐶𝑋 + cells
↔ 𝐷𝐶𝑋 + cells
↑ 𝐵𝑟𝑑𝑈 +cells
↔ 𝐵𝑟𝑑𝑈 +cells
↑ 𝑁𝑒𝑢𝑁 + 𝐵𝑟𝑑𝑈 +
↔ 𝑁𝑒𝑢𝑁 + 𝐵𝑟𝑑𝑈 +
↔ 𝐷𝐶𝑋 + cell migration
↑ 𝐷𝐶𝑋 + cell migration
↑ Secondary and tertiary spines
↑ Total dendritic length
↑ Total number of branches
↑ Number of spines
↔ Number of spines
↑ 𝐷𝐶𝑋 + cells
↑ 𝐵𝑟𝑑𝑈 +cells
↔ pair-pulse ratio
↑ fEPSP slope and slope %
↑ LTP magnitude %
↔ fEPSP slope %
↔ LTP magnitude
↑ LTP amplitude and slope
↔ LTP amplitude and slope
↑ LTP amplitude and slope
↔ LTP amplitude and slope

Hippocampus
(dentate gyrus)

IHC

rTMS + AM251 1 mg/kg
AM251 1 mg/kg
rTMS + AM251 1 mg/kg
AM251 1 mg/kg
CBD 30 mg/kg

Hippocampus
(subgranular zone)
Hippocampus
(dentate gyrus)

IHC
IHC

AM251 0.3 mg/kg and/or CBD 30 mg/kg
AM630 0.3 mg/kg and AM630 + CBD
CBD 30 mg/kg , AM251 0.3 mg/kg and AM630 + CBD
CBD + AM251 and AM630 0.3 mg/kg
AM630 + CBD, AM251 0.3 mg/kg and/or CBD 30 mg/kg
AM630 0.3 mg/kg
AM251, AM630, AM251 + CBD and AM630 + CBD
CBD 30 mg/kg

Hippocampus
(dentate gyrus)

IHC

JZL184 8 mg/kg

Electrophys

JZL184 8 mg/kg
JZL184 8 mg/kg + picrotoxin

vSubiculumNucleus
accumbens
pathway

Electrophys

Day 23: WIN55,212-2 0.5 mg/kg
WIN55,212-2 0.5 mg/kg + AM251 0.3 mg/kg
RU-38486 10 mg/kg and WIN55,212-2 + RU-38486
Day 28: WIN55,212-2

Subjects
18-22g Adult Male
Kunming Mice
32-38 g Male ICR Mice
(42 days old)
18-22g Adult Male
Kunming Mice
32-38 g Male ICR Mice
(42 days old)
167-183g Male Sprague
Dawley Rats (49 days
old)
25-35 g Male Swiss ICR
Mice (60-90 days old)
180-230 g Male Sprague
Dawley Adult Rats

Author, year
Jin, Yu, Tian, Zhang, & Quan, 2015

Male C57BL/6J Mice
(90 days old)
20-26g Male C57BL/6J
Mice (56-63 days old)

Campos et al., 2013

Male C57BL/6J Mice
(56-70 days old)

Zhang et al., 2015

Male Sprague Dawley
Rats (45 days old)

Segev, Rubin, Abush, Richter-Levin,
& Akirav, 2014

Xu et al., 2015
Jin, Yu, Tian, Zhang, & Quan, 2015
Xu et al., 2015
Hwang et al., 2020
García-Gutiérrez, Pérez-Ortiz,
Gutiérrez-Adán, & Manzanares, 2010
Wang et al., 2014

Fogaça, Campos, Coelho, Duman, &
Guimarães, 2018

Table 4. Stress-Related Effects. ↓ and ↑ represent a statistically significant decrease or increase (respectively) while ↔ represents a
non-significant or unclear change. Drug doses are administered intraperitoneally and consistent within the article unless stated
otherwise. p.o. – oral, i.v. – intravenous, ELISA – enzyme-linked immunosorbent assay, qRT-PCR - quantitative real time polymerase
chain reaction, IHC – immunohistochemistry, Electrophys – electrophysiology, rTMS – repetitive transcranial magnetic simulation,
CBD – Cannabidiol, BDNF – brain derived neurotropic factor, BrdU – bromodeoxyuridine, DCX – doublecortin, NeuN – neuronal
nuclear protein, fEPSP – field excitatory post synaptic potential, LTP – long term potentiation.
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Cannabinoid Efficacy
The excel files containing the full datasets with moderators and the R markdown
code file containing all statistical analyses are both available on the Open Science
Framework (https://osf.io/csgmf/). The main mixed effects model nesting the effect sizes
within measurement type studies, study groups, and articles with effect size weights
nested within control groups revealed a significant pooled SMD of 0.4456 (95% CI
0.0498 – 0.8415, p = 0.0274), indicating that CB administration rescues the overall
negative effects of CUS on anhedonia, learned helplessness, novelty suppressed
feeding, and exploration anxiety in comparison to placebo. Separate meta-analyses
nesting the effect sizes within study groups and articles with effect size weights nested
within control groups were conducted for each of the five test measurements. Entries into
the anxiogenic context revealed a SMD of 0.6231 (95% CI -0.0095 – 1.2558, p = 0.0535)
an effect that was likely unable to reach significance because it has less statistical power
than the main model. These separate analyses suggest that future studies should continue
to investigate the effect of CBs on entries into the anxiogenic context in CUS. In the
separate meta-analysis for learned helplessness (i.e. immobility time), an exploratory
moderator analysis on the effect of the studies’ test time revealed that test time did not
significantly affect the SMD ! = 0.2244 (95% CI -0.0376 – 0.4865, p = 0.0932)
indicating that the immobility time measurement was not affected by the test time. This
result should be interpreted with caution because this model has less statistical power
than the main model.
Moderator analyses were conducted on a mixed effects model nesting the effect
sizes within study groups and articles with effect size weights nested within control
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groups. Measurement type studies was included in the model as the second moderator for
all moderator analyses. The effect of co-treatments was originally proposed to be
addressed by adjusting the studies’ weight, but without a quantifiable measurement to
adjust the weight of co-treatment studies, this effect was instead addressed with a
moderator analysis. A moderator analysis on the model revealed that for CB treatments
that did not include an additional treatment (i.e. not a co-treatment) there was a
significant SMD of 0.7919 (95% CI 0.1387 – 1.445, p = 0.0175). This co-treatment
moderator analysis is likely a better representation of the efficacy of CBs on stresscoping behaviors in CUS since a sizeable amount of co-treatment effect sizes combined
CB agonists with CB antagonists. In support of this interpretation, a moderator analysis
on the model revealed that for CBs that enhance the ECS there was a significant SMD of
0.7809 (95% CI 0.1281 – 1.4337, p = 0.019). These data support the continuation of
research on the effect of CBs which enhance the ECS on stress-coping behaviors in CUS.
The model was not significantly moderated by the method of administration. For
CBs administered systemically there was SMD of 0.6231 (95% CI -0.0453 – 1.2916, p =
0.0677) and for CBs administered in a site-specific manner there was a SMD of -0.028
(95% CI -1.1401 – 1.0841, p = 0.9607). The method of administration moderator analysis
should be interpreted with caution as there were only nine effect sizes with site-specific
intracranial administration. A moderator analysis on the model revealed that for CB
administration during CUS there was a significant SMD of 0.8043 (95% CI 0.3022 –
1.3065, p = 0.0017). These data suggest that CBs are more efficacious at regulating the
HPA axis during CUS rather than after CUS. For the timing of CB administration relative
to CUS, the “after” and “both” moderators should be interpreted with caution. The “both”
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moderator should be interpreted with caution due to statistical power, with 97 effect sizes
for the “during” moderator, 49 effect sizes for the “after” moderator, and only 19 effect
sizes for the “both” moderator. The “after” moderator should be interpreted with caution
because a proportion of the effect sizes administering CBs after CUS also administered
CBs once intracranially.
The model was significantly moderated by the number of CB administrations,
meaning that every additional administration increased the SMD by a value of ! = 0.0262
(95% CI 0.0026 – 0.0499, p = 0.0295). Hillard and colleagues hypothesize that the effects
of CBs on the HPA axis depends on the eCB tone (i.e. the amount of eCBs in an
individual’s ECS) with a high eCB tone facilitating effective HPA axis termination
(Hillard et al., 2018). Therefore, it is possible that chronic CB treatment artificially
maintains a high eCB tone. The model was also significantly moderated by the dose,
meaning that every additional mg/kg increased the SMD by a value of ! = 0.0209 (95%
CI 0.0078 – 0.0339, p = 0.0018). It is important to take into consideration that the dose
moderator was conducted on a dataset which removed site specific and co-treatment
effect sizes. The effect of dose possibly reflects the development of tolerance to CBs and
the need to maintain this high eCB tone, thereby supporting the need to continue
investigating CB-based drugs that do not directly target the CB receptors.
A moderator analysis on the model revealed that for mice there was a significant
SMD of 0.7772 (95% CI 0.0512 – 1.5032, p = 0.0359). Although the differences between
rats and mice exposed to CUS has not been formally investigated, it appears that at least
anecdotally, mice have higher stress reactivity than rats (Kent Scientific Corporation,
2019). If this observation is true, then it is possible that CBs exhibit greater efficacy on
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mice because mice exhibit a greater reaction to CUS. Regardless, further investigation is
needed on the differences between species on the effects of CBs on stress-coping
behaviors in CUS.
Surprisingly the model was not significantly moderated by the number of days of
stress ! = 0.0096 (95% CI -0.0122 – 0.0315, p = 0.3878). These data suggest that the
efficacy of CBs on stress-coping behaviors is not significantly affected by the severity of
the CUS paradigm. Therefore, future studies should focus less on the severity of the CUS
paradigm and focus more on conducting CUS with female rodents or disease models (e.g.
for depression and anxiety) to investigate the efficacy of CBs on stress-coping behaviors
in CUS. The lack of effect sizes needed to conduct the proposed moderator analyses on
the effects of model (control vs. disease) and sex (males vs. females) further emphasizes
the need to investigate this gap in the literature.
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Figure 3. Anhedonia. Meta-analysis of studies investigating the effect of CB
administration in CUS on anhedonia (i.e. sucrose intake or preference). All measures are
of % sucrose preference unless stated otherwise. BW – body weight, SMD –
Standardized mean difference, CI – confidence interval, rTMS – repetitive transcranial
magnetic simulation, CBD – Cannabidiol, OEA – oleoyl-ethanolamide, VMH – ventral
medial hypothalamus, CA1 – first region in the hippocampus, RIM – rimonabant, ACEA
- Arachidonyl-2-chloroethylamide.
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Figure 4. Learned Helplessness. Meta-analysis of studies investigating the effect of CB
administration in CUS on learned helplessness (i.e. immobility time in seconds for the
forced swim test or tail suspension test). Sec – total time of the test in seconds used for
analysis, FST – forced swim test, TST – tail suspension test, SMD – Standardized mean
difference, CI – confidence interval, AEA – anandamide, rTMS – repetitive transcranial
magnetic simulation, RIM – rimonabant, BCP - !-Caryophyllene, vmPFC – ventromedial
prefrontal cortex, OEA – oleoyl-ethanolamide, BLA – basolateral amygdala, CBD –
Cannabidiol.
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Figure 5. Novelty Suppressed Feeding. Meta-analysis of studies investigating the effect
of CB administration in CUS on anxiety in the novelty suppressed feeding test (i.e.
latency to consume food in a novel environment). SMD – Standardized mean difference,
CI – confidence interval, CBD – Cannabidiol, GFAP-TK – glial fibrillary acidic protein
thymidine kinase transgenic mice, rTMS – repetitive transcranial magnetic simulation,
CA1 – first region in the hippocampus, RIM – rimonabant.
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Figure 6. Time in the Anxiogenic Context. Meta-analysis of studies investigating the
effect of CB administration in CUS on exploration anxiety (i.e. % or total time spent in
the anxiogenic context). Sec – total time of the test in seconds, EPM – elevated plus
maze, OFT – open field test, EZM – elevated zero maze, LDB – light dark box test, SMD
– Standardized mean difference, CI – confidence interval, CBD – Cannabidiol, GFAPTK – glial fibrillary acidic protein thymidine kinase transgenic mice, THC –
tetrahydrocannabinol, RIM – rimonabant.

42

Figure 7. Entries into the Anxiogenic Context. Meta-analysis of studies investigating the
effect of CB administration in CUS on exploration anxiety (i.e. % or # of entries into the
anxiogenic context). EPM – elevated plus maze, OFT – open field test, LDB – light dark
box test SMD – Standardized mean difference, CI – confidence interval, CBD –
Cannabidiol, GFAP-TK – glial fibrillary acidic protein thymidine kinase transgenic mice,
THC – tetrahydrocannabinol.
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Bias Assessment
The risk of bias across articles can be viewed in Figure 8. Overall, preclinical
research can greatly benefit from reporting the measures taken to reduce the risk of bias
(Macleod et al., 2015). When evaluating baseline characteristics, all articles reported sex
and usually either the weight or age of the subjects. In neuroscience research, both
characteristics are important when considering measures such as the effect of a treatment
or the effect on the subject’s brain, respectively. When conducting research with rodents,
it is not always possible to control for litter effects initially due to housing constraints.
Unfortunately, not a single article statistically controlled for the variance shared by
littermates, which has the potential of increasing the likelihood of committing an error
(Sequeira-Cordero, Salas-Bastos, Fornaguera, & Brenes, 2019). Controlling for baseline
characteristics is especially important in collaborative research, which resulted in the two
“high” scores.
When evaluating allocation concealment, most articles were “unclear” about how
the CUS schedule was generated. Two articles explicitly stated that the same weekly
schedule was repeated which can negatively impact the efficacy of the CUS paradigm
since the subjects are more likely to habituate to a weekly schedule in comparison to a
completely randomized schedule (Franklin et al., 2012).
When evaluating random housing, several articles received “high” scores by
stating that the experimental group was housed in a different room than the control group.
Housing different groups in different rooms can result in disproportionate exposure to
noise and differences in colony maintenance by animal technicians, thereby influencing
stress-coping behaviors. Environmental conditions such illumination and temperature can
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differ between cages on the top and bottom shelf (Hooijmans et al., 2014). Since
differences in illumination and temperature can also influence stress-coping behaviors,
environmental conditions need to be properly controlled for by randomly shuffling shelf
locations between groups (Haller et al., 2007; Hooijmans et al., 2014). In other instances,
the housing conditions were different between the control and experimental groups (i.e.
individually or group housed). With social stressors such as isolation and overcrowding,
it is important that the housing conditions are comparable between control and
experimental groups since the housing conditions can also influence stress-coping
behaviors (Sequeira-Cordero et al., 2019).
When evaluating incomplete outcome data, although two articles received “high”
scores, five of the more recent articles received “low” scores for reporting the initial size
of their groups, the group sizes for analysis, and communicating sources of attrition or
exclusions in their article. In alignment with encouraging this trend towards explicit
communication of group sizes, sample size calculations should also be communicated.
Low statistical power, which is commonly observed in preclinical neuroscience research,
has tremendous consequences in the reliability and reproducibility of results due to
overestimated effect sizes (Button et al., 2013).
When evaluating selective outcome reporting, although three articles received
“high” scores, it is important to recognize the eight articles with “low” scores that
explicitly stated when data was not shown in their article. However, with unlimited space
to provide complete datasets with non-significant results in online supplementary
material or to publish these results publicly using resources such as the Open Science
Framework, it is sobering that only six out of the 26 articles provided supplementary
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material. When additional information was directly requested through email, it is
demoralizing to report that only one researcher was able to provide their dataset. Two
researchers responded saying they no longer had the original dataset, and another
researcher was unable to find their original data. In order to avoid the need to directly
contact researchers for additional information, providing all data in non-graphical form
and all analysis calculations has immense potential to facilitate the reproducibility of
work and improve the quality of meta-analytic work in efforts to reduce unnecessary
animal use (Hooijmans et al., 2010).
Generally, there was more reporting on conflicts of interest, blinding, and
randomization of groups (i.e. sequence generation). These trends of increased reporting in
preclinical neuroscience research are in line with other types of preclinical research
which should provide hope that there is potential to facilitate continued improvement in
reporting measures taken to reduce the risk of bias (Macleod et al., 2015). It is also
interesting to note that despite a subset of articles monitoring body weight and sucrose
preference throughout stress for validation of the CUS paradigm, only one article
investigated the locomotor effects of the drugs administered (Onaivi et al., 2008). When
investigating exploration anxiety, it would be impactful to screen for the locomotor
effects of the drugs administered or provide a baseline within-subject measure of
locomotion to control for locomotor effects of the drug. A within-subject baseline
locomotion measurements in exploration anxiety tests should be considered as standard.
Similarly to how the latency to consume food in the home cage was measured after all of
the novelty suppressed feeding tests. This within-subject measure that was taken in
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addition to the latency to consume food in a novel environment to control for possible
anxiogenic or orexigenic effects of drugs.
In line with controlling for the effects of a drug, it is also important to control for
the stress-inducing effects of injections and any effects of the solvent that is administered
to the experimental group by administering the same exact solution without the drug (i.e.
a vehicle) to the control group. Therefore, vehicle administration was added as an
evaluation criterion. Although the majority of articles reported this form of control in
their research design, it was surprising to discover that four articles received an “unclear”
score for not explicitly stating the implementation of such a crucial control in
pharmacology research.
A separate sensitivity analysis was conducted by generating a bias score (Table
7). This bias score was calculated for each article by adding one point for every “low”
evaluation score and subtracting one point for every “high” evaluation score, then adding
two points to all of the articles so that the lowest bias score was zero. Two articles were
removed for having the lowest bias scores, revealing a significant SMD of 0.4547 (95%
CI 0.0388 – 0.8705, p = 0.0321) which is not substantially different than the pooled SMD
of 0.4456 (95% CI 0.0498 – 0.8415, p = 0.0274).
As clearly observed in Figure 8, the most common evaluation score across all
measures (aside from the conflict of interest and vehicle measures) is “unclear” which
suggests an overestimation of the treatment effects and a need for more explicit reporting
of measures taken to reduce the risk of bias (Reis et al., 2019).
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Figure 8. Risk of Bias Across Articles. Evaluation of included articles.
Publication Bias and Heterogeneity
The main mixed effects meta-analysis model is a multi-level model (i.e. effect
sizes nested within measurement type studies, study groups, and articles) and utilizes
effect size weights nested within control groups to address multiple levels of
dependencies. Currently, there is no single method to evaluate publication bias while
addressing sample dependency (Rodgers & Pustejovsky, 2020). Ignoring dependency and
assuming that this meta-analysis is a univariate model rather than a multi-level mixed
effects model can inflate the type I error rate (Rodgers & Pustejovsky, 2020). Therefore,
two analyses for publication bias were conducted. The first analysis conducts an Eggar
regression on the funnel plot with the nested weights. The second analysis conducts an
Eggar regression on the funnel plot with the nested weights but is only for a subset of the
effect sizes by selecting the single largest effect size for each of the 26 included articles
(assuming that articles are published based on their largest effect size). An Egger
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regression on the funnel plot of the full dataset (Figure 9) revealed the significant
presence of asymmetry (t = -5.005, df = 163, p < 0.001). Whereas an Egger regression on
the funnel plot of the subset data (Figure 10) approached the significant presence of
asymmetry (t = -2.053, df = 24, p = 0.0511). Conflicting findings from these two methods
of analysis have been previously reported (Rodgers & Pustejovsky, 2020). Since the
Egger regression on the funnel plot of the subset data approached the significant presence
of asymmetry, these Eggar regressions suggest that publication bias is present in the
dataset (Reis et al., 2019). Asymmetrical funnel plots are due to a lack of non-significant
and opposing findings published (Reis et al., 2019).
In a multi-level mixed effects model nesting the effect sizes within study groups
and articles but not within measurement type studies, there was a moderate amount of
heterogeneity across studies (# ! = 69.5218%), indicating inconsistent results (Melsen et
al., 2014). As expected based on methodological heterogeneity, there was more
heterogeneity between studies (# ! = 46.4898%) than within studies (# ! = 23.0319%).
Separate analyses by test measurement identified anhedonia as the most heterogenous
measurement (# ! = 91.2125%) with a much greater proportion of heterogeneity between
studies (# ! = 86.1742%) than within studies (# ! = 5.038%). Entries in the anxiety context
was the least heterogenous measurement (# ! = 64.5820%) with more heterogeneity
between studies (# ! = 51.2359%) than within studies (# ! = 13.3462%).
High heterogeneity and funnel plot asymmetry negatively affect meta-analyses as
they weaken the external validity of the meta-analysis findings (Reis et al., 2019). The
most effective moderator in reducing heterogeneity was the time the drug was
administered relative to CUS (# ! = 56.6541%). None of the heterogeneity was between
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studies (# ! = 0%) and all of the heterogeneity was within studies (# ! = 56.6541%)
indicating that all the variances of effect sizes by this moderator was due to sampling
error or chance (Vesterinen et al., 2014). Although it is tempting to speculate that this
within study heterogeneity might be due to differences from significant moderators that
were not identified in this meta-analysis, these data suggest a need to implement multiple
control groups in future investigations on the effect of CBs administered during CUS.
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Figure 9. Complete Funnel Plot. Funnel plot of all 165 effect sizes using nested weights.

Figure 10. Article Specific Funnel Plot. Funnel plot of the largest effect size for each of
the 26 articles in the meta-analysis using nested weights.
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CHAPTER VI
DISCUSSION
Implications and Future Directions
Article Characteristics
This meta-analysis contains 26 articles and 35 study groups for a total of 165
effect sizes (Figure 1). Out of the 26 articles, 21 articles contained studies in which CBs
were administered through intraperitoneal injections, 19 articles contained studies in
which CBs were administered during CUS, and 15 articles contained studies in which
CBs were administered daily.
Cannabinoid-Related Effects
Some interesting CB-related effects that need to be highlighted are in regard to
CB1R expression and eCB content in the hippocampus (Table 3). Chronic stress
downregulates CB1R in the hippocampus, hypothalamus, striatum, and dorsal root
ganglion (Morena et al., 2016). These findings can partially explain why CBs reduced or
did not have an effect on CB1R expression in the cingulate, hippocampus, and midbrain
(Bortolato et al., 2007; Lomazzo et al., 2015). Chronic stress upregulates CB1R in the
PFC, and in this same study the vehicle CUS group demonstrated significantly increased
CB1R expression compared to the vehicle non-stressed group (Bortolato et al., 2007).
Therefore, URB597 at a dose of 0.3 mg/kg was likely able to inhibit enough FAAH to
increase levels of AEA (although not statistically enough compared to vehicle CUS) to
where it could reduce CB1R genetic expression in URB597-treated CUS group compared
to the vehicle CUS group in the PFC (Bortolato et al., 2007; Morena et al., 2016). This
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speculation is supported by the significantly increased levels of AEA and PEA in the PFC
by a 1 mg/kg dose of URB597 (Lomazzo et al., 2015).
Surprisingly, URB597 at a dose of 0.3 and 1 mg/kg did not have any significant
effect on AEA levels in the hippocampus compared to vehicle CUS groups (Bortolato et
al., 2007; Lomazzo et al., 2015). Although there is one study reporting CUS-induced
reductions of AEA levels and another reporting CUS-induced increases of FAAH protein
expression, several studies did not find any significant effects of CUS on AEA levels or
FAAH activity (Bortolato et al., 2007; Hill et al., 2005; Lomazzo et al., 2015; Morena et
al., 2016). It is tempting to attribute the lack of significant effect of URB597 in the
hippocampus to the former observations, but additional studies are needed to elucidate
the effects of CBs in the hippocampus during CUS. On the other hand, JZL184 at a dose
of 8 mg/kg significantly increases 2-AG levels in the cingulate, PFC, hypothalamus,
midbrain, and hippocampus because it inhibits MAGL (Lomazzo et al., 2015). In the
hippocampus, 2-AG levels are reduced by CUS (Hill et al., 2005; Morena et al., 2016).
Therefore, it appears that in the hippocampus JZL184 has the ability to rescue this CUSinduced reduction of 2-AG levels via inhibition of MAGL (the main catabolic enzyme for
2-AG). The differences between the effects of CUS on 2-AG and AEA levels in the
hippocampus requires further investigation.
Stress-Related Effects
The most common stress-related biochemical measurements were focused on
neuronal survival, growth, and synaptic plasticity. Five articles measured genetic and
protein expression of brain derived neurotropic factor (BDNF). BDNF is important for
neuronal survival, and its expression can be reduced by stress (Jin et al., 2015). In the
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PFC, OEA and high levels of absorbed CBD significantly increase levels of BDNF in
comparison to CUS vehicle groups (Jin et al., 2015; Xu et al., 2019). The effects of CBs
on BDNF expression in the hippocampus are inconsistent which is likely due to the
reduction of hippocampal volume observed in MDD (Franklin et al., 2012; Ulrich-Lai &
Herman, 2009). All together these data suggest CBs that substantially enhance the ECS
generally rescue CUS-induced decreases in BDNF expression and CBs which inhibit the
ECS do not seem to rescue CUS-induced decreases in BDNF expression (GarcíaGutiérrez et al., 2010; Hwang et al., 2020; Jin et al., 2015; H.-n. Wang et al., 2014; Xu et
al., 2019). These data suggest that some CBs can be neuroprotective against CUSinduced reductions in BDNF expression.
For measuring neurogenesis, bromodeoxyuridine is neuronal marker for cell
proliferation which can be combined with doublecortin and neuronal nuclear protein to
identify immature and mature neurons, respectively (Fogaça et al., 2018). In the
hippocampus, the effects of CBs on neuronal growth are inconsistent (Table 4). However,
the proliferative effects of CBs appear to be mediated by CBs that substantially enhance
the ECS, more specifically with increases in the eCB 2-AG and possibly through a CB2R
mediated mechanism (Campos et al., 2013; Fogaça et al., 2018; H.-n. Wang et al., 2014;
Zhang et al., 2015). Finally, within the hippocampus and in extended hippocampal
projections to the nucleus accumbens, it appears that enhancing the ECS can increase
measurements of long-term potential which is regarded as the strengthening of synaptic
transmission (Segev et al., 2014; Zhang et al., 2015).

54
Cannabinoid Efficacy
CB administration rescued the overall negative effects of CUS on anhedonia,
learned helplessness, novelty suppressed feeding, and exploration anxiety with a pooled
SMD of 0.4456 (95% CI 0.0498 – 0.8415, p = 0.0274) in comparison to the vehicle CUS
group. The protective effects of CBs against CUS are significantly larger in mice, with
CB treatments that are not co-treatments, with CBs that enhances the ECS, and with CBs
administered during CUS. The effects of CBs in CUS also significantly increase with
increased doses and administration frequencies. Therefore, future studies investigating
the effects of CBs in CUS should reliably enhance the eCB tone during CUS. Based on
these results, it would be interesting to investigate the therapeutic index of different CBs
in CUS.
The protective effects of CBs were significantly greater in mice compared to rats,
which supports previous findings that reported differences between rodent species on the
effects of CBs in anxiety measurements (i.e. proportion of time and entries into open
arms) in the elevated plus maze (Haller et al., 2007). In a study from Haller and
colleagues, WIN55,212-2 (at a dose of 3 mg/kg in mice and 1 mg/kg in rats) was
anxiolytic in mice and anxiogenic in rats (Haller et al., 2007). In this same study, AM251
(at a dose of 3 mg/kg in mice and 5 mg/kg in rats) was anxiogenic in mice but had no
effect on rats (Haller et al., 2007). In addition to differences between species, differences
between mouse strains in both stress reactivity and effects of CB administration on
anxiety behaviors have been reported (Franklin et al., 2012; Haller et al., 2007). Together
these findings emphasize the influence of species and strains on stress-coping behaviors
and highlight a need for further investigation.
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In line with these findings, future research on the effect of CBs on rodent models
of depression and anxiety in comparison to “control” models are needed. There is also a
need for research on sex differences in the effects of CB in CUS. In the laboratory that
included females in their research, one article conducted an open field test and the other
an elevated plus maze and forced swim test (Ferizovic et al., 2020; Jankovic et al., 2020).
In the elevated plus maze, CUS significantly reduced the percentage of entries into the
anxiogenic context in both sexes and this reduction was greater in females (Jankovic et
al., 2020). URB597 rescued CUS-induced reductions on the percentage of entries into the
anxiogenic context in both sexes (Jankovic et al., 2020). Furthermore, CUS significantly
reduced the time females spent in the anxiogenic context, but there were no significant
effects in males or in URB597-treated CUS groups of either sex (Jankovic et al., 2020).
In the open field test, URB597-treated CUS rats of both sexes rescued CUS-induced
reductions in ambulation in anxiogenic context but the time spent in the anxiogenic was
only rescued in males (Ferizovic et al., 2020). These data indicate that CUS-induced
reductions in exploration anxiety are greater in females and that females respond
differently to CB-based treatments when compared to males. It is possible that URB597
only rescued time spent in the anxiogenic context in males because CUS-induced
reductions in time spent in the anxiogenic context was greater in females (Ferizovic et al.,
2020; Jankovic et al., 2020). In the forced swim test, URB597-treated CUS rats of both
sexes rescued CUS-induced increases in immobility time and this effect was greater in
males (Jankovic et al., 2020). Similarly to exploration anxiety, the differences in
treatment efficacy between sexes in the context of learned helplessness might be due to
the increased effects of CUS-induced increase in immobility in females compared to
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males. Regardless, the differences between sexes on the effect of CBs in CUS needs to be
investigated further. Research on sex differences in CUS can be immensely impactful
when considering the increased prevalence of stress-related psychopathologies in female
humans and rodents compared to males (Franklin et al., 2012). Unfortunately, there were
not enough effect sizes to be able to conduct the proposed moderator analyses for the
effects of model (control vs. disease) and sex (males vs. females), which again highlights
the need for the inclusion of these groups in future studies.
Limitations
Bias Assessment
It is important to interpret the findings of this meta-analysis with caution as
evaluation of these articles revealed that the most common modified SYRCLE’s risk of
bias evaluation score across all measures (aside from the conflict of interest statement
and vehicle administration) was “unclear” (Hooijmans et al., 2014). Based on these bias
evaluations, it is important to not disregard the potential for bias in the included articles.
Publication Bias and Heterogeneity
An important limitation in meta-analysis research pertains to methodological
heterogeneity. High heterogeneity of meta-analyses reduces the predictive validity of the
meta-analysis results (Melsen, Bootsma, Rovers, & Bonten, 2014). Heterogeneity was
quantified from # ! in order to appropriately analyze and best interpret the predictive
validity of the meta-analysis results (Higgins et al., 2003; Reade, Delaney, Bailey, &
Angus, 2008). Although a random effects model was selected to best demonstrate the
distribution of the studies estimated effects, results revealed moderate heterogeneity
across studies (# ! = 69.5218%) indicating inconsistent results (Melsen et al., 2014). The
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most effective moderator in reducing heterogeneity was the time the drug was
administered relative to CUS (# ! = 56.6541%), which suggests that CBs have different
efficacies depending on when they are administered in relation to stress.
A second limitation in meta-analysis research that is especially prevalent in
preclinical neuroscience research is small sample sizes, which reduces the reliability and
validity of the studies’ outcomes (Button et al., 2013; Tipton, 2015). Small sample sizes
can also lead to publication bias (Button et al., 2013; Reis et al., 2019). Therefore, the
third limitation in this meta-analysis is publication bias, which weakens external validity
of meta-analyses (Button et al., 2013; Reis et al., 2019). Publication bias funnel plots are
assessed using Egger regression (Egger et al., 1997). An Egger regression was conducted
on two versions of funnel plots (Figure 9 and Figure 10) in consideration to sample
dependency. An Egger regression on the funnel plot of the full dataset (Figure 9) revealed
the significant presence of asymmetry, whereas an Egger regression on the funnel plot of
the subset data (Figure 10) approached the significant presence of asymmetry. Since the
Egger regression on the funnel plot of the subset data approached the significant presence
of asymmetry, these Egger regressions suggest that publication bias is present in this
dataset. As previously stated, high heterogeneity and funnel plot asymmetry negatively
affect meta-analyses as they weaken the external validity of the meta-analysis findings
(Reis et al., 2019). Therefore, the interpretation of CB efficacy in stress-coping behaviors
in CUS is limited by heterogeneity and publication bias and likely impacted by the small
group sample sizes in the meta-analysis. In consideration of these limitations, the sources
of heterogeneity and evaluation of biases still provide valuable guidance in improving the
external validity of future studies. It is also important to note that a significant pooled
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SMD despite moderate heterogeneity suggests that CBs are efficacious at rescuing the
overall negative effects of CUS in a variety of context, therefore supporting the external
validity of CB efficacy (Reade et al., 2008).
In the interest of statistical power, the definition of the CUS paradigm was
selected to be as inclusive as possible, and the most common stress-coping behavior tests
were subjected to the meta-analysis. Although there were 70 measurement type studies
across the five test measurements included in this meta-analysis, the statistical power of
this considerably large number of studies was negatively impacted by heterogeneity,
publication bias, and various levels of dependencies. Although the dependency was
largely addressed with a multi-level mixed effects model and with effect size weights
nested within control groups, attempts to elucidate sources heterogeneity and publication
bias were less successful. It is possible that there are sources of methodological
heterogeneity that were not reported in the articles thereby contributing to the limitations
of meta-analysis research (Vesterinen et al., 2014). Fortunately, corresponding
neuroendocrinological measurements, which were predicted to collect small aggregated
samples, were indexed by brain region and systematically reviewed in order to contribute
to a meaningful overview of the current literature.
The final limitation is the search syntax which did not include all known CBs.
The broadening of the search syntax from CUS to simply chronic stress increased the
scope of the search and allowed all CUS paradigms to be included regardless or not if
they used the specific keyword of CUS. The lack of additional articles found from the
exploratory search on article recommendations provided by the Mendeley reference
manager software, from contacting 53 researchers for grey literature, and from the
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backwards and forwards citation tracking of the included articles, are all a testament in
support of a comprehensive search strategy.
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CHAPTER VI
CONCLUSIONS
What I Have Learned
By conducting this meta-analysis, I have learned a tremendous amount about the
realities of conducting neuroscience research. When facilitating collaboration, I have
learned that there is a balance between allowing colleagues the opportunity to set their
own deadlines and enforcing your own deadlines. I have also learned how valuable it is to
plan in advance and in as much detail as possible to factor in plenty of buffer time in
consideration of Murphy’s Law.
With regards to realistic techniques to improve my own future research designs, I
am committed to calculating the sample size using a formal power calculation rather than
depending on historical precedent, and at the very least, I will report said sample size
calculation in my published research (Button et al., 2013; Macleod et al., 2015). I will
encourage myself to conduct a pre- and post-test, within-subject design as an additional
control for the outcome measurements investigated or at the least conduct a preliminary
study to screen for potential effects of a drug on the behavioral outcome that I am
measuring. I will also be explicit about the contents of the vehicle solution when
describing how the drug was prepared. I will ensure that I create counterbalanced groups
and explicitly state as such (Hooijmans et al., 2014). I will report subjects’ sex, age, and
weight and also control for the variance shared by littermates statistically by
incorporating the mothers as a variable in the analysis (Hooijmans et al., 2014; SequeiraCordero et al., 2019). For paradigms such as CUS, I will schedule my stressors no more
than one week in advance to prevent myself from foreseeing intervention allocations
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(Hooijmans et al., 2014). I will make sure to shuffle the shelf locations of my control and
experimental groups and avoid labeling cages by group to prevent my own performance
bias (Hooijmans et al., 2014). I will randomize the order of subjects being tested and their
allocation to different types of analysis (Hooijmans et al., 2014). I will also implement
means to blind both behavioral and biochemical analysis by asking a colleague to rename
data folders that contain behavioral videos or biochemical images. I will report the initial
group sizes, the group sizes for analysis, and explicitly state why any animals were
removed or excluded from the study (Hooijmans et al., 2014). All data, including ones
that are commonly not reported such as weight measurements, will be available in their
entirety in the supplementary materials or on platforms such as the Open Science
Framework. In addition, all tables used to generate figures and all analyses will be made
publicly available. I will report effect sizes to facilitate future meta-analyses. I will also
be fully transparent in the event that exploratory analyses are conducted or if any
unanticipated changes occurred in the research process (Moreau & Gamble, 2020).
Finally, I will ensure that my published research contains a conflict of interest statement
(Macleod et al., 2015).
Summary
The results of this current study comprehensively summarize the existing
preclinical literature on the effect of CBs on stress-coping behaviors and
neuroendocrinological measures in CUS. Despite revealing a significant pooled SMD in
the model, the focus of this meta-analysis was to guide future preclinical study designs
rather than evaluate the overall efficacy of CBs. These data highlight gaps in the
literature by suggesting the sample characteristics for which such pharmacotherapies
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should be preclinically tested and designed for. Furthermore, these data can help guide
future preclinical research away from unnecessary replication of study designs and from
studies which appear less efficacious (Vesterinen et al., 2014). Identifying the study
designs which appear less efficacious will refocus research efforts towards preclinical
studies that are more translationally impactful. Overall, these data provide a framework
for the future direction of preclinical research investigating CB-based pharmacotherapies
for stress-related psychopathologies. In alignment with the guidance this meta-analysis
hopes to provide, the bias evaluation in this meta-analysis echoes the importance of
reporting measurements which need to be taken to reduce the risk of bias in preclinical
research in order to facilitate reproducible research and improve the external validity of
preclinical research.
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CHAPTER IX
APPENDIX
Date
10/27/2020

1/27/2021
2/13/2021

2/1/2021

2/18/2021

3/3/2021

3/15/21

3/22/21
3/26/21

Protocol Deviations
Description
Rationale
“Chronic unpredictable stress, defined Increase the number of
as: #1 intermittent #2 heterotypic
included articles with the type
stressors at minimum #3 daily
of stress analyzed as a
frequency occurring for over a #4
moderator
week or longer“ criterion broadened to
“Chronic stress (i.e. stress is
administered for more than one day)”
Searched Mendeley reference manager Relevant articles were being
suggested articles
suggested and wanted to be
systematically searched
“Control group (i.e. vehicle
Noticed articles administering
administration)” criterion broadened to multiple treatments did not
“Control group (i.e. vehicle
use proper vehicles for each
administration) *Improper vehicles
treatment
will be weighed less”
“Administration of a cannabinoid (e.g. Frequency of treatment was
WIN55,212-2) *Cotreatments will be
already planned to be
weighed less” explicitly broadened to
addressed as a moderator in
include acute administration
the published protocol
“Chronic stress (i.e. stress is
Was not feasible to examine
administered for more than one day)”
all of the included articles
criterion restricted to “Chronic
Unpredictable Stress (i.e. variable
stress is administered for more than
seven days)”
Excluded reviews were not backwards Included articles that were
citation tracked
backwards and forwards
citation tracked did not yield
any additional articles
Vehicle implemented in weight
Noticed articles which did not
calculation
explicitly state the contents of
their vehicle
Exploratory moderator analysis of
time in learned helplessness metaanalysis
Co-treatments and vehicle addressed
as a moderator and evaluation criteria,
respectively

Check that the time of the test
was not affecting immobility
time
Literature review did not
provide a numeric value to
adjust the weight

Impact
Increased search
results

Addition to the
search strategy
Increased included
articles that were
weight adjusted
Clarification
(increased included
articles)
Excluded articles
and reduced
heterogeneity

Removed from the
initial search
strategy
Reduces the weight
of effect sizes in
articles which did
not use a proper
control treatment
Investigates
heterogeneity
Investigates
heterogeneity and
evaluates control
group

Table 5. Protocol Deviations. Adapted from Moreau, D., & Gamble, B. (2020, January
7). Conducting a Meta-Analysis in the Age of Open Science: Tools, Tips, and Practical
Recommendations. https://doi.org/10.31234/osf.io/t5dwg
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SYSTEMATIC REVIEW PROTOCOL FOR ANIMAL INTERVENTION STUDIES
FORMAT BY SYRCLE (WWW.SYRCLE.NL)
VERSION 2.0 (DECEMBER 2014)
Item # Section/Subsection/Item

Description

A. General
1.

2.

3.

4.
5.
6.
7.
8.

9.

The Effect of Cannabinoids on Stress-Coping
Behaviors and Neuroendocrinological
Title of the review
Measures in Chronic Stress: A Preclinical
Systematic Review and Meta-Analysis
Reuveni N. (Conceived project and
independent Researcher #1), Carlson C.
Authors (names,
(Independent Researcher #2), Freeman S.
affiliations, contributions)
(Reviewer), and Schwartz S (Statistician). All
affiliated with Utah State University.
Meter D. (Meta-Analysis Advice), Renshaw
T. (Meta-Analysis Advice), Weingart S.
(Librarian), McFarland M. (Librarian),
Other contributors (names, Barrett T. (Statistician), Downs J. (Statistical
affiliations, contributions) Advice), and Culianos D (Statistical Advice).
McFarland affiliated with the University of
Utah and everyone else is affiliated with
Utah State University.
Contact person + e-mail
Noa Reuveni
address
nreuveni1@gmail.com
Utah State University’s College of Education
Funding sources/sponsors & Human Services Graduate Student
Research Award is funding Carlson’s work.
Conflicts of interest
None
Date and location of
protocol registration
Registration number (if
applicable)
Conducted preliminary searches. McFarland
conducted the Embase search (11/6/20).
Stage of review at time of
The remaining databases have not been
registration
searched yet.

Check for
approval
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B. Objectives
Background

10.

11.
12.
13.

14.

15.

Substance use disorder (SUD) is one of
many stress related psychiatric disorders
(Bluett et al., 2017). Cannabinoids (CBs)
demonstrate a biphasic effect on stress,
with low doses being anxiolytic and high
doses being anxiogenic (Scarante et al.,
2017). Due to the mounting evidence
supporting endogenous CB’s fundamental
What is already known
role in regulating the hypothalamic pituitary
about this
adrenal (HPA) axis stress response, this
disease/model/interventio
project proposes to systematically review
n? Why is it important to
the current literature on the adverse and
do this review?
therapeutic effects of CBs on stress-coping
behaviors and neuroendocrinological
measures (Hillard, Beatka, & Sarvaideo,
2018). Elucidating the direction of future
cannabinoid research is in line with
reducing animal use, as defined in the 3Rs
(Hooijmans, Tillema, Leenaars, & RitskesHoitinga, 2010).
Research question
Specify the disease/health Vulnerability to stress related psychiatric
problem of interest
disorders (e.g. SUD).
Specify the
Rats and Mice
population/species studied
Specify the
Chronic stress (i.e. stress is administered for
intervention/exposure
more than one day).
Within publication control (i.e. stress
vehicle group). Robust variance estimation
Specify the control
meta-regression will be used to address
population
dependency between measurements in the
same sample (Tipton, 2015).
Behavioural measures are organized into
the following categories: elevated plus
maze, elevated zero maze, elevated t maze,
open field test, light-dark box test, hole
Specify the outcome
board test, social interaction test, novelty
measures
suppressed feeding test, novelty induced
hypophagia test, object recognition test,
operant conflict test, fear conditioning,
forced swim test, sucrose preference test,
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acoustic startle response and prepulse
inhibition, marble burying test. Examples of
specific outcome measures include:
weight lost, total distance travelled in
meters, total time spent in anxiety context
in seconds, total distance in anxiety context
in meters, total distance in non-anxiety
context in meters, total distance in
between contexts in meters, total rearing
time in seconds, total rearing frequency,
total stretch attempt posture frequency,
total grooming time in seconds, total
grooming frequency, total digging time in
seconds, total digging frequency, entries or
crossing over to the anxiety context, total
exploration time in seconds , latency to
enter the anxiety context in seconds, total
freezing time in seconds, freezing
frequency, latency to approach food in
seconds, % approached (approached
test/total test), total sniffing time in
seconds, total sniffing frequency, amount of
food consumed in grams, familiar object
exploration frequency, novel object
exploration frequency, basal startle
response amplitude, prepulse inhibition
startle response amplitude, acoustic startle
response latency in seconds, acoustic
startle response amplitude, freezing
behavior in seconds, ultrasonic
vocalizations in kilohertz, raspatory
frequency peak time in seconds, velocity
(activity burst in meters / second, %
unpunished responding
(unpunished/baseline) % punished
responding (punished/baseline), immobility
time in seconds, swimming time in seconds,
climbing time in seconds, sucrose intake,
sucrose preference (sucrose intake/total
fluid intake), and total number of marbles
buried.
Neuroendocrinological measures are
organized into the following categories:
organ weight, hormone concentrations,
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16.

State your research
question (based on items
11-15)

genetic, chemical (i.e. Microdialysis),
Assays, Histology, Blot, Post translational
modifications, in situ hybridization, tract
tracing, electrophysiology, and
optogenetics. Example of a specific
outcome: plasma corticosterone or
adrenocorticotropic levels.
Primary question: do cannabinoids have a
protective or destructive effect on the HPA
axis and complimentary stress-coping
behaviors in the context of chronic stress?
Secondary questions: does the type of
stress, severity of stress, biological model,
dosage, method of administration, timing of
administration, and pharmacological effect
influence the direction (protective or
destructive) and efficacy of cannabinoids?

C. Methods
Search and study identification

x MEDLINE via PubMed □ Web of
Science

17.

Identify literature
databases to search (e.g.
PubMed, Embase, Web of
science)

x SCOPUS
x EMBASE
x Other, namely: Psychology and
Behavioral Sciences Collection, APA
PsychINFO, CINAHL Complete, and
ProQuest Dissertations & Theses Global

□Specific journal(s), namely:

18.

(MICE) OR (RATS)
AND
(CHRONIC MILD STRESS) OR (CHRONIC
UNPREDICTABLE STRESS) OR (CHRONIC
VARIABLE STRESS) OR (CHRONIC
Define electronic search
HETEROTYPIC STRESS) OR (HETEROTYPIC
strategies (e.g. use the step STRESS) OR (CHRONIC STRESS) OR
by step search guide15 and (CHRONIC HOMOTYPIC STRESS) OR
animal search filters20, 21)
(CHRONIC REPEATED STRESS) OR (CHRONIC
PREDICTABLE STRESS) OR (STRESS COPING)
OR (STRESS RESILIENCE) OR (STRESS
VULNERABILITY) OR (HYPOTHALAMIC
PITUITARY ADRENAL) OR (HYPOTHALAMIC
PITUITARY ADRENAL AXIS) OR
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(CORTICOTROPIN RELEASING HORMONE)
OR (CORTICOTROPIN RELEASING FACTOR)
OR (CORTICOSTERONE) OR
(ADRENOCORTICOTROPIC HORMONE)
AND
(CANNABINOID RECEPTOR) OR
(CANNABINOID 1 RECEPTOR) OR
(CANNABINOID 2 RECEPTOR) OR (CB1
CANNABINOID RECEPTORS) OR (CB2
CANNABINOID RECEPTORS) OR (CANNABIS)
OR (CANNABIS SATIVA) OR
(TETRAHYDROCANNABINOL) OR
(TETRAHYDROCANNABINOLIC ACID) OR
(CANNABINOID) OR (CANNABINOIDS) OR
(MARIJUANA) OR (CANNABIDIOL) OR
(CANNABINOL) OR (DRONABINOL) OR
(MARINOL) OR (NABILONE) OR (CESAMET)
OR (ANANDAMIDE) OR
(ARACHIDONOYLGLYCEROL) OR
(RIMONABANT) OR (SR141716) OR (FATTY
ACID AMIDE HYDROLASE) OR (NABIXIMOLS)
OR (ACYLGLYCEROL LIPASE) OR (WIN55 212
2) OR (WIN55212 2) OR (EXOGENOUS
CANNABINOIDS) OR (SYNTHETIC
CANNABINOIDS) OR (ARACHIDONOYL
ETHANOLAMIDE)
*full syntax search provided at the end of
the protocol

19.

Identify other sources for
study identification

x Reference lists of included studies
□Books
x Reference lists of relevant reviews
□Conference proceedings, namely:
x Contacting authors/ organisations,

namely: Authors of included studies, the
National Institute of Health, and the
Hebrew University Multidisciplinary Center
on Cannabinoid Research
Other, namely:
Forward tracking of the citations of
included studies will be conducted using
Google Scholar’s “cited by” feature for
newer literature.

□
20.

Define search strategy for
these other sources
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21.

22.

23.

24.

25.

26.

27.

Study selection
Define screening phases
(e.g. pre-screening based
on title/abstract, full text
screening, both)

First phase: title and abstract
Second phase: full text screening

(a) Two independent researchers will
conduct both screening phases. (b)
Discrepancies will be resolved by discussion
with the reviewer (third independent
researcher) that will make the final
decision.
Define all inclusion and exclusion criteria based on:
Inclusion criteria: within the study there is a
control group receiving stress and vehicle
Type of study (design)
administration
Exclusion criteria: no control group
Type of animals/population
Inclusion criteria: mice or rats
(e.g. age, gender, disease
Exclusion criteria: not mice nor rats
model)
Inclusion criteria: repeated administration
of any cannabinoid at any dosage at any
time and at any frequency relative to the
stress paradigm (administration of a
cannabinoid with another non-cannabinoid
Type of intervention (e.g.
compound will also be included and the
dosage, timing, frequency)
study will be statistically weighed less in
order to take the effects of the other
compound into consideration)
Exclusion criteria: cannabinoid is only
administered once
Inclusion criteria: Stress coping behaviors
and/or
Outcome measures
Neuroendocrinological measures
Exclusion criteria: no measures related to
stress
Inclusion criteria: English references
Exclusion criteria: non-English references
Although this criteria poses as an inherent
Language restrictions
bias against non-English references, there
appears to be minimal benefit in the
translation of non-English references (Jüni,
Holenstein, Sterne, Bartlett, & Egger, 2002)
Specify (a) the number of
reviewers per screening
phase and (b) how
discrepancies will be
resolved

75

28.

Publication date
restrictions

29.

Other

30.

Sort and prioritize your
exclusion criteria per
selection phase

Inclusion criteria: Oldest studies to
November 2020
Exclusion criteria: none
Inclusion criteria: primary source peer
reviewed article and unpublished data
Exclusion criteria: secondary sources (e.g.
reviews) and conference abstracts due to
lack of readily available data
Inclusion criteria: chronic stress (i.e. stress
is administered for more than one day)
Exclusion criteria: only one day of stress
Title/abstract phase:
1. Article text available in English
2. Subjects are rats or mice
3. Administration of a cannabinoid
(e.g. WIN55,212-2) *Cotreatments
will be weighed less
4. Outcome data related to anxiety
tests (e.g. Open Field test) or stresscoping behaviors (e.g. SelfGrooming) and/or accompanying
biochemical data (e.g. related to the
endogenous cannabinoid system or
hypothalamic pituitary adrenal axis
stress response)
5. Chronic stress (i.e. stress is
administered for more than one
day).
6. Control group (i.e. vehicle
administration)
7. Primary Research
Full-text phase:
1. Article text available in English
2. Subjects are rats or mice
3. Administration of a cannabinoid
(e.g. WIN55,212-2) *Cotreatments
will be weighed less
4. Outcome data related to anxiety
tests (e.g. Open Field test) or stresscoping behaviors (e.g. SelfGrooming) and/or accompanying
biochemical data (e.g. related to the
endogenous cannabinoid system or
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31.

32.

33.

34.

hypothalamic pituitary adrenal axis
stress response)
5. Chronic stress (i.e. stress is
administered for more than one
day).
6. Control group (i.e. vehicle
administration)
7. Primary Research
Study characteristics to be extracted (for assessment of external validity, reporting
quality)
**full proposed codebook available on the Open Science Framework
DOI 10.17605/OSF.IO/CSGMF
- Authors (chr)
Study ID (e.g. authors,
- Year (num)
year)
- Journal (chr)
- Number of experimental groups
(num)
- Number of animals per group
(num)
- Total animals (num)
- Enrichment (fct)
- Handling frequency per day
(num)
Study design
- Handling duration in days (num)
characteristics (e.g.
- Food and water regimen (chr)
experimental groups,
- Light cycle (chr)
number of animals)
- Temperature of the
experimental room or condition
(e.g. water bath in forced swim
test) (num)
- Duration of housing in days
(num)
- Time of day (fct)
- Light or dark (fct)
- Strain (chr)
Animal model
- Sex (fct)
characteristics (e.g.
- Age in days (num)
species, gender, disease
- Single/group housing (fct)
induction)
- Housing temperature in Celsius
(num)
Intervention characteristics
- Number of different stressors
(e.g. intervention, timing,
(num)
duration)
- Intensity of stressors (fct)
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Average frequency of stressors
per day (num)
- Disrupting circadian rhythm (fct)
- Size of chamber (chr)
- Dosage in mg/kg (num)
- Timing of injection in hours
relative to paradigm (chr)
- Solvent (chr)
- Vehicle information (chr)
- Cannabinoid (chr)
- Mean acoustic startle response
in seconds (num)
- Latency to enter the
room/eat/engage with novel
stimulus in seconds (num)
- Percentage of time spent in
Outcome measures
elevated/open arms (num)
- Mean grooming behavior in licks
(num)
- Forced swim immobility time in
seconds (num)
- Digging behaviour in seconds
(num)
Please see the full proposed codebook
Other (e.g. drop-outs)
available on the Open Science Framework
DOI 10.17605/OSF.IO/CSGMF
Assessment risk of bias (internal validity) or study quality
Specify (a) the number of
(a) Two independent researchers will
reviewers assessing the risk independently assess the risk of bias. (b)
of bias/study quality in
Discrepancies will be resolved by discussion
each study and (b) how
with the reviewer (third independent
discrepancies will be
researcher) that will make the final
resolved
decision.
-

35.

36.

37.

□By use of SYRCLE's Risk of Bias tool
x By use of SYRCLE’s Risk of Bias tool,
4

38.

Define criteria to assess (a)
the internal validity of
included studies (e.g.
selection, performance,
detection and attrition
bias) and/or (b) other study
quality measures (e.g.
reporting quality, power)

adapted as follows: adding control for
locomotor effects, conflicts of interest, and
sample size calculations to the evaluation
By use of CAMARADES' study quality
checklist, e.g 22
By use of CAMARADES' study quality
checklist, adapted as follows:
Other criteria, namely:

□
□
□

78

39.

40.

41.

42.

43.

44.

45.

46.

Collection of outcome data
For each outcome
measure, define the type
of data to be extracted
(e.g.
continuous/dichotomous,
unit of measurement)
Methods for data
extraction/retrieval (e.g.
first extraction from graphs
using a digital screen ruler,
then contacting authors)
Specify (a) the number of
reviewers extracting data
and (b) how discrepancies
will be resolved

Please see the full proposed codebook
available on the Open Science Framework
DOI 10.17605/OSF.IO/CSGMF
The data is extracted from graphs, if
applicable, using WebPlotDigitizer. The
original authors will be also be contacted to
request the raw data.
(a) Two independent researchers will
independently extract the data. (b)
Discrepancies will be resolved by discussion
with the reviewer (third independent
researcher) that will make the final
decision.

Data analysis/synthesis
Specify (per outcome
Stress coping behaviors with continuous
measure) how you are
measures will be combined through metaplanning to
analysis.
combine/compare the data Neuroendocrinological measures will be
(e.g. descriptive summary, combined onto a table with a descriptive
meta-analysis)
summary for each study.
Specify (per outcome
Meta-analysis will be carried out if there is
measure) how it will be
sufficient replicated studies (#>3) looking at
decided whether a metaequivalent outcomes.
analysis will be performed
If a meta-analysis seems feasible/sensible, specify (for each outcome measure):
The effect measure to be
used (e.g. mean difference, Standardized mean difference will be used
standardized mean
for continuous measures of each stress
difference, risk ratio, odds coping behavior.
ratio)
Random effects model will be performed
The statistical model of
because it assumes distribution of the
analysis (e.g. random or
studies estimated effects (Melsen,
fixed effects model)
Bootsma, Rovers, & Bonten, 2014).
Between- study heterogeneity will be
The statistical methods to
evaluated using the # ! statistic with # ! more
assess heterogeneity (e.g.
than 25%, 50%, and 75% selected to reflect
I2, Q)
low, moderate, and high heterogeneity
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47.

48.

49.

50.

respectively (Higgins, Thompson, Deeks, &
Altman, 2003).
Species (rats vs mice), type of stress
Which study characteristics (heterotypic vs homotypic), dosage, timing
will be examined as
of administration relative to stress,
potential source of
biological model, frequency of treatment,
heterogeneity (subgroup
treatment pharmacology, severity of stress,
analysis)
method of administration, and
pharmacological effect (e.g. agonist)
Any sensitivity analyses
A sensitivity analysis with the high risk-ofyou propose to perform
bias studies removed may be performed.
Other details meta-analysis
(e.g. correction for multiple Correction for multiple use of control group
testing, correction for
will be addressed using robust variance
multiple use of control
estimation meta-regression (Tipton, 2015).
group)
Publication bias funnel plots will be
The method for
assessed using Egger regression and
assessment of publication corrected for using trim and fill if possible
bias
(Egger, Smith, Schneider, & Minder, 1997;
Vesterinen et al., 2014).

Final approval by (names,
affiliations):

Date:
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Database
(Platform)
1. Scopus
(Elsevier)

2. Embase
(Elsevier)

Search Syntax (ROW #1 AND ROW #2 AND ROW
#3)
( TITLE-ABS-KEY ( {MICE} OR {RATS} ) )
( TITLE-ABS-KEY ( {CHRONIC MILD STRESS} OR
{CHRONIC UNPREDICTABLE STRESS} OR
{CHRONIC VARIABLE STRESS} OR {CHRONIC
HETEROTYPIC STRESS} OR {HETEROTYPIC
STRESS} OR {CHRONIC STRESS} OR {CHRONIC
HOMOTYPIC STRESS} OR {CHRONIC REPEATED
STRESS} OR {CHRONIC PREDICTABLE
STRESS} OR {STRESS COPING} OR {STRESS
RESILIENCE} OR {STRESS VULNERABILITY} OR
{HYPOTHALAMIC PITUITARY ADRENAL} OR
{HYPOTHALAMIC PITUITARY ADRENAL AXIS}
OR {CORTICOTROPIN RELEASING HORMONE} OR
{CORTICOTROPIN RELEASING FACTOR} OR
{CORTICOSTERONE} OR {ADRENOCORTICOTROP
IC HORMONE} ) )
( TITLE-ABS-KEY ( {CANNABINOID RECEPTOR}
OR {CANNABINOID 1 RECEPTOR} OR
{CANNABINOID 2 RECEPTOR} OR {CB1
CANNABINOID RECEPTORS} OR {CB2
CANNABINOID RECEPTORS} OR {CANNABIS} OR
{CANNABIS SATIVA} OR
{TETRAHYDROCANNABINOL} OR
{TETRAHYDROCANNABINOLIC ACID} OR
{CANNABINOID} OR {CANNABINOIDS} OR
{MARIJUANA} OR {CANNABIDIOL} OR
{CANNABINOL} OR {DRONABINOL} OR
{MARINOL} OR {NABILONE} OR {CESAMET} OR
{ANANDAMIDE} OR
{ARACHIDONOYLGLYCEROL} OR
{RIMONABANT} OR {SR141716} OR {FATTY ACID
AMIDE HYDROLASE} OR {NABIXIMOLS}
OR {ACYLGLYCEROL LIPASE} OR {WIN55 212 2}
OR {WIN55212 2} OR {EXOGENOUS
CANNABINOIDS} OR {SYNTHETIC
CANNABINOIDS} OR {ARACHIDONOYL
ETHANOLAMIDE} ) )
#16 #15 NOT 'conference abstract'/it 430 [Final set]
#15 #13 AND #14 517
#14 'mouse'/exp OR 'rat'/exp OR mouse:ti,ab,kw OR
mice:ti,ab,kw OR mus:ti,ab,kw OR rat:ti,ab,kw OR
rats:ti,ab,kw OR rattus:ti,ab,kw [Rat,mouse
set] 3984429
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#13 #7 AND #12 1140 Cannabinoids + Chronic
stress/HPA set]
#12 #8 OR #9 OR #10 OR #11 Chronic stress/HPA
set]
164056
#11 'hypothalamic pituitary adrenal':ti,ab,kw OR
'hypothalamic pituitary adrenal axis':ti,ab,kw OR
'corticotropin releasing hormone':ti,ab,kw OR
'corticotropin releasing factor':ti,ab,kw OR
'corticosterone':ti,ab,kw OR 'adrenocorticotropic
hormone':ti,ab,kw 63105
#10 'corticotropin releasing factor'/de OR 'cortisone'/de
OR 'corticotropin'/de 108652
#9
'chronic mild stress':ti,ab,kw OR 'chronic
unpredictable stress':ti,ab,kw OR 'chronic variable
stress':ti,ab,kw OR 'chronic heterotypic stress':ti,ab,kw
OR 'heterotypic stress':ti,ab,kw OR 'chronic
stress':ti,ab,kw OR 'chronic homotypic stress':ti,ab,kw OR
'chronic repeated stress':ti,ab,kw OR 'chronic predictable
stress':ti,ab,kw OR 'stress coping':ti,ab,kw OR 'stress
resilience':ti,ab,kw OR 'stress vulnerability':ti,ab,kw
18292
#8
'chronic stress'/de OR 'chronic unpredictable
stress'/de 10876
#7
#3 OR #6 [cannabinoids/receptors set]
90701
#6
#4 OR #5 [cannabinoid receptor set]
18339
#5
(receptor* NEAR/2 (cannabinoid* OR
tetrahydrocannabinol*)):ti,ab,kw 12814
#4
'cannabinoid receptor'/de OR 'cannabinoid 1
receptor'/de OR 'cannabinoid 2 receptor'/de
14990
#3
#1 OR #2 89637 [cannabinoids set]
#2
'cannabis':ti,ab,kw OR 'cannabis sativa':ti,ab,kw
OR 'tetrahydrocannabinol':ti,ab,kw OR
'tetrahydrocannabinolic acid':ti,ab,kw OR
'cannabinoid':ti,ab,kw OR 'cannabinoids':ti,ab,kw OR
'marijuana':ti,ab,kw OR 'cannabidiol':ti,ab,kw OR
'cannabinol':ti,ab,kw OR 'dronabinol':ti,ab,kw OR
'marinol':ti,ab,kw OR 'nabilone':ti,ab,kw OR
'cesamet':ti,ab,kw OR 'anandamide':ti,ab,kw OR
'arachidonoylglycerol':ti,ab,kw OR 'rimonabant':ti,ab,kw
OR 'sr141716':ti,ab,kw OR 'fatty acid amide
hydrolase':ti,ab,kw OR 'nabiximols':ti,ab,kw OR
'acylglycerol lipase':ti,ab,kw OR 'win55 212 2':ti,ab,kw
OR 'win55212 2':ti,ab,kw OR 'exogenous
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3.
Psychology
and
Behavioral
Sciences
Collection
(EBSCOhost
)
4. APA
PsychINFO
(EBSCOhost
)
5. PubMed
(National
Library of
Medicine)
6. CINAHL
Complete
(EBSCOhost
)

7. ProQuest
Dissertations
& Theses
Global
(ProQuest)

cannabinoids':ti,ab,kw OR 'synthetic
cannabinoids':ti,ab,kw OR 'arachidonoyl
ethanolamide':ti,ab,kw
68172
#1
'cannabinoid'/exp
71558
(MICE) OR (RATS)
(CHRONIC MILD STRESS) OR (CHRONIC
UNPREDICTABLE STRESS) OR (CHRONIC
VARIABLE STRESS) OR (CHRONIC HETEROTYPIC
STRESS) OR (HETEROTYPIC STRESS) OR
(CHRONIC STRESS) OR (CHRONIC HOMOTYPIC
STRESS) OR (CHRONIC REPEATED STRESS) OR
(CHRONIC PREDICTABLE STRESS) OR (STRESS
COPING) OR (STRESS RESILIENCE) OR (STRESS
VULNERABILITY) OR (HYPOTHALAMIC
PITUITARY ADRENAL) OR (HYPOTHALAMIC
PITUITARY ADRENAL AXIS) OR
(CORTICOTROPIN RELEASING HORMONE) OR
(CORTICOTROPIN RELEASING FACTOR) OR
(CORTICOSTERONE) OR
(ADRENOCORTICOTROPIC HORMONE)
(CANNABINOID RECEPTOR) OR (CANNABINOID 1
RECEPTOR) OR (CANNABINOID 2 RECEPTOR) OR
(CB1 CANNABINOID RECEPTORS) OR (CB2
CANNABINOID RECEPTORS) OR (CANNABIS) OR
(CANNABIS SATIVA) OR
(TETRAHYDROCANNABINOL) OR
(TETRAHYDROCANNABINOLIC ACID) OR
(CANNABINOID) OR (CANNABINOIDS) OR
(MARIJUANA) OR (CANNABIDIOL) OR
(CANNABINOL) OR (DRONABINOL) OR
(MARINOL) OR (NABILONE) OR (CESAMET) OR
(ANANDAMIDE) OR
(ARACHIDONOYLGLYCEROL) OR (RIMONABANT)
OR (SR141716) OR (FATTY ACID AMIDE
HYDROLASE) OR (NABIXIMOLS) OR
(ACYLGLYCEROL LIPASE) OR (WIN55 212 2) OR
(WIN55212 2) OR (EXOGENOUS CANNABINOIDS)
OR (SYNTHETIC CANNABINOIDS) OR
(ARACHIDONOYL ETHANOLAMIDE)
noft(MICE OR RATS)
noft("CHRONIC MILD STRESS" OR "CHRONIC
UNPREDICTABLE STRESS" OR "CHRONIC
VARIABLE STRESS" OR "CHRONIC HETEROTYPIC
STRESS" OR "HETEROTYPIC STRESS" OR
“CHRONIC STRESS” OR “CHRONIC HOMOTYPIC
STRESS” OR “CHRONIC REPEATED STRESS” OR
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“CHRONIC PREDICTABLE STRESS” OR "STRESS
COPING" OR "STRESS RESILIENCE" OR "STRESS
VULNERABILITY" OR "HYPOTHALAMIC
PITUITARY ADRENAL" OR "HYPOTHALAMIC
PITUITARY ADRENAL AXIS" OR
"CORTICOTROPIN RELEASING HORMONE" OR
"CORTICOTROPIN RELEASING FACTOR" OR
"CORTICOSTERONE" OR
"ADRENOCORTICOTROPIC HORMONE")
noft("CANNABINOID RECEPTOR" OR
"CANNABINOID 1 RECEPTOR" OR "CANNABINOID
2 RECEPTOR" OR "CB1 CANNABINOID
RECEPTORS" OR "CB2 CANNABINOID
RECEPTORS" OR "CANNABIS" OR "CANNABIS
SATIVA" OR "TETRAHYDROCANNABINOL" OR
"TETRAHYDROCANNABINOLIC ACID" OR
"CANNABINOID" OR "CANNABINOIDS" OR
"MARIJUANA" OR "CANNABIDIOL" OR
"CANNABINOL" OR "DRONABINOL" OR
"MARINOL" OR "NABILONE" OR "CESAMET" OR
"ANANDAMIDE" OR
"ARACHIDONOYLGLYCEROL" OR
"RIMONABANT" OR "SR141716" OR "FATTY ACID
AMIDE HYDROLASE" OR "NABIXIMOLS" OR
"ACYLGLYCEROL LIPASE" OR "WIN55 212 2" OR
"WIN55212 2" OR "EXOGENOUS CANNABINOIDS"
OR "SYNTHETIC CANNABINOIDS" OR
"ARACHIDONOYL ETHANOLAMIDE")
Table 6. Search Terms. Adapted from Moreau, D., & Gamble, B. (2020, January 7).
Conducting a Meta-Analysis in the Age of Open Science: Tools, Tips, and Practical
Recommendations. https://doi.org/10.31234/osf.io/t5dwg
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ID

Lab

Species

Stress_Days

High_num

Bias

Bortolato (2007)

1

Rats

70

2

3

Buran (2017)

2

Mice

49

2

2

Campos (2013)

3

Mice

14

2

4

Fang (2018)

4

Rats

21

0

7

Ferizovic (2020)

5

Rats

42

0

4

Fogaca (2018)

3

Mice

14

3

2

Fokos (2010)

6

Rats

10

0

5

Gall (2020)

7

Rats

28

0

8

Garcia Gutierrez (2010)

8

Mice

49

1

7

Griebel (2005)

9

Mice

49

2

1

Hill (2004)

10

Rats

21

0

5

Hwang (2020)

11

Rats

28

0

5

Ishiguro (2018)

12

Mice

14

0

6

Jankovic (2020)

5

Rats

42

0

4

Jin (2015)

13

Mice

28

1

6

Lomazzo (2015)

14

Mice

73

0

4

Lomazzo (2017)

14

Mice

73

0

4

McLaughlin (2013)

10

Rats

21

0

9

Onaivi (2008)

12

Mice

28

4

0

Pekala (2018)

15

Mice

27

0

5

Segev (2014)

16

Rats

21

1

4

Wang (2014)

17

Rats

28

0

6

Wang (2016)

18

Rats

18

1

3

Xu (2019)

19

Mice

35

0

4

Zhang (2015)

20

Mice

35

0

6

Zhong (2014)

20

Mice

35

0

4

Table 7. Article Moderators. Article level moderators that were imported into R for
analysis. For the full datasets, including study-level moderators, please visit the Open
Science Framework (https://osf.io/csgmf/). ID – article identification, Stress_days –
number of days of stress, High_num, number of “high” evaluation scores, Bias –
calculated bias score.

